1895 lines
284 KiB
Text
1895 lines
284 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK609085">
|
|
<meta name="ncbi_domain" content="niceng243er7">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK609085/?report=reader">
|
|
<meta name="ncbi_pagename" content="Routine pharmacological management of secondary and tertiary adrenal insufficiency - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Routine pharmacological management of secondary and tertiary adrenal insufficiency - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="citation_title" content="Routine pharmacological management of secondary and tertiary adrenal insufficiency">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2024/08">
|
|
<meta name="citation_pmid" content="39541484">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK609085/">
|
|
<meta name="citation_keywords" content="Adrenal Insufficiency">
|
|
<meta name="citation_keywords" content="Adrenal Hyperplasia, Congenital">
|
|
<meta name="citation_keywords" content="Glucocorticoids">
|
|
<meta name="citation_keywords" content="Treatment Outcome">
|
|
<meta name="citation_keywords" content="Cost-Benefit Analysis">
|
|
<meta name="citation_keywords" content="Infant">
|
|
<meta name="citation_keywords" content="Child, Preschool">
|
|
<meta name="citation_keywords" content="Child">
|
|
<meta name="citation_keywords" content="Adolescent">
|
|
<meta name="citation_keywords" content="Young Adult">
|
|
<meta name="citation_keywords" content="Adult">
|
|
<meta name="citation_keywords" content="Middle Aged">
|
|
<meta name="citation_keywords" content="Aged">
|
|
<meta name="citation_keywords" content="Aged, 80 and over">
|
|
<meta name="citation_keywords" content="Humans">
|
|
<meta name="citation_keywords" content="Review">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Routine pharmacological management of secondary and tertiary adrenal insufficiency">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Date" content="2024/08">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK609085/">
|
|
<meta name="og:title" content="Routine pharmacological management of secondary and tertiary adrenal insufficiency">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK609085/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng243er7-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng243er7/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK609085/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8DDE337D6B73A10000000000650057.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK609085/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK609085/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK609085/&text=Routine%20pharmacological%20management%20of%20secondary%20and%20tertiary%20adrenal%20insufficiency"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK609085/?report=classic">Switch to classic view</a><a href="/books/n/niceng243er7/pdf/">PDF (2.8M)</a><a href="/books/n/niceng243er7/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK609085%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8DDE337D6B73A10000000000650057.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng243er7-lrg.png" alt="Cover of Routine pharmacological management of secondary and tertiary adrenal insufficiency" /></a></div><div class="bkr_bib"><h1 id="_NBK609085_"><span itemprop="name">Routine pharmacological management of secondary and tertiary adrenal insufficiency</span></h1><div class="subtitle">Adrenal insufficiency: identification and management</div><p><b>Evidence review G</b></p><p><i>NICE Guideline, No. 243</i></p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2024 Aug</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-6469-7</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2024.</div></div><div class="bkr_clear"></div></div><div id="niceng243er7.s1"><h2 id="_niceng243er7_s1_">1. Routine pharmacological management of secondary and tertiary adrenal insufficiency</h2><div id="niceng243er7.s1.1"><h3>1.1. Review question</h3><p>What is the clinical and cost effectiveness of glucocorticoids for the routine management of secondary and tertiary adrenal insufficiency?</p><div id="niceng243er7.s1.1.1"><h4>1.1.1. Introduction</h4><p>People with secondary and tertiary adrenal Insufficiency are dependent on glucocorticoids for survival because the pituitary and hypothalamus do not send the hormone signals to the adrenal glands to make cortisol and require daily replacement of the missing hormone, cortisol.</p><p>In current practice, glucocorticoid replacement therapy is usually given as either oral hydrocortisone or prednisolone. Hydrocortisone is typically administered in two to four divided doses, with a higher dose often administered in the morning in an attempt to mimic the natural circadian rhythm. Novel formulations of modified-release hydrocortisone allow for less frequent dosing, although their place in standard therapy is still not clear. Prednisolone has a longer duration of action and may be given once daily. There is considerable variation in the use of glucocorticoids in clinical practice and no current consensus on the optimum replacement therapy.</p><p>Both under and over-replacement of glucocorticoids may contribute to comorbidities and long-term complications. Appropriate glucocorticoid replacement therapy is therefore required to reduce these risks, maintain well-being, and improve outcomes.</p><p>Babies, children, and young people with AI go through a period of rapid growth and change requiring different doses and dosing schedules to adult patients and frequent adjustment to their doses to optimise growth and well-being.</p><p>In this chapter, we review the different glucocorticoid therapies to establish which is the most clinically and cost-effective pharmacological treatment for patients with a diagnosis of secondary or tertiary adrenal insufficiency.</p></div><div id="niceng243er7.s1.1.2"><h4>1.1.2. Summary of the protocol</h4><p>For full details see the review protocol in <a href="#niceng243er7.appa">Appendix A</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab1"><a href="/books/NBK609085/table/niceng243er7.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img" rid-ob="figobniceng243er7tab1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab1"><a href="/books/NBK609085/table/niceng243er7.tab1/?report=objectonly" target="object" rid-ob="figobniceng243er7tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div></div><div id="niceng243er7.s1.1.3"><h4>1.1.3. Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>. Methods specific to this review question are described in the review protocol in <a href="#niceng243er7.appa">Appendix A</a> and the <a href="/books/NBK609085/bin/NG243-Methods.pdf">methods</a> document.</p><p>Declarations of interest were recorded according to <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s conflicts of interest policy</a>.</p><p>This evidence review includes evidence relating to use of glucocorticoids for routine management of secondary and tertiary adrenal insufficiency.</p></div><div id="niceng243er7.s1.1.4"><h4>1.1.4. Effectiveness evidence</h4><div id="niceng243er7.s1.1.4.1"><h5>1.1.4.1. Included studies</h5><p>Four randomised crossover controlled trials (RCTs, 6 papers) were included in the review<a class="bibr" href="#niceng243er7.ref1" rid="niceng243er7.ref1"><sup>1</sup></a><sup>–</sup><a class="bibr" href="#niceng243er7.ref4" rid="niceng243er7.ref4"><sup>4</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng243er7.ref6" rid="niceng243er7.ref6"><sup>6</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng243er7.ref8" rid="niceng243er7.ref8"><sup>8</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng243er7.ref9" rid="niceng243er7.ref9"><sup>9</sup></a>; these are summarised in <a href="/books/NBK609085/table/niceng243er7.tab2/?report=objectonly" target="object" rid-ob="figobniceng243er7tab2">Table 2</a> below. Evidence from these studies is summarised in the clinical evidence summary below (<a href="/books/NBK609085/table/niceng243er7.tab3/?report=objectonly" target="object" rid-ob="figobniceng243er7tab3">Table 3</a>).</p><p>See also the study selection flow chart in <a href="#niceng243er7.appc">Appendix C</a>, study evidence tables in <a href="#niceng243er7.appd">Appendix D</a>, forest plots in <a href="#niceng243er7.appe">Appendix E</a> and GRADE tables in <a href="#niceng243er7.appf">Appendix F</a>.</p><p>The studies compared different doses of oral hydrocortisone. These studies included the following comparisons:
|
|
<ul><li class="half_rhythm"><div>Hydrocortisone: 5mg 2x daily vs. 10mg 2x daily<a class="bibr" href="#niceng243er7.ref1" rid="niceng243er7.ref1"><sup>1</sup></a>, 1 week follow-up</div></li><li class="half_rhythm"><div>Hydrocortisone: Dose A (20 mg 0800 h, 10 mg 1600 h) vs Dose B (10 mg 0800 h and 1600 h) vs Dose C (10 mg 0800 h and 5 mg 1600 h)<a class="bibr" href="#niceng243er7.ref2" rid="niceng243er7.ref2"><sup>2</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng243er7.ref3" rid="niceng243er7.ref3"><sup>3</sup></a>, 6-week follow-up</div></li><li class="half_rhythm"><div>Hydrocortisone: Dose A [10mg/5mg HC] vs Dose B [10mg/5mg/5mg HC]<a class="bibr" href="#niceng243er7.ref4" rid="niceng243er7.ref4"><sup>4</sup></a>, 4-week follow-up</div></li><li class="half_rhythm"><div>Hydrocortisone: Low dose [0.2-0.3 mg/kg] vs High dose [0.4-0.6 mg/kg]<a class="bibr" href="#niceng243er7.ref8" rid="niceng243er7.ref8"><sup>8</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng243er7.ref9" rid="niceng243er7.ref9"><sup>9</sup></a>’ 10-week follow-up</div></li><li class="half_rhythm"><div>Hydrocortisone: Once-daily modified-release tablets (MR-HC) vs. standard glucocorticoid<a class="bibr" href="#niceng243er7.ref6" rid="niceng243er7.ref6"><sup>6</sup></a></div></li></ul></p><p>These studies all included adult patients with secondary adrenal insufficiency (SAI). SAI was defined in all studies based on cortisol levels. However, different criteria were used to classify patients across the studies:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Agha 2004: Included patients with partial adrenocorticotropic hormone (ACTH) deficiency, defined as fasting 08·00 h total serum cortisol exceeding 200 nmol/l with a stimulated peak value of less than 500 nmol/L</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Behan 2011, Behan 2016: Included patients with severe ACTH deficiency, defined as fasting morning total serum cortisol concentration <100 nmol/l and a stimulated peak value of <400 nmol/L. All patients in these studies had been diagnosed with and treated for pituitary tumours 3-18 years prior to study enrolment.</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Benson 2012: Included patients with SAI, defined as peak cortisol =< 450 nmol/L</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Wermeus Buning 2015, Wermeus Buning 2016: Included patients who had been diagnosed with adrenal insufficiency in adulthood. Fasting morning cortisol levels used to define SAI are not specified.</p></dd></dl></dl></p><blockquote><p>One study (Isidori 2018) included a mixed population of adults with primary AI (n=44 Addison’s disease) or SAI (n=45). Results were presented together so it was not possible to separate the data. These outcomes have been downgraded for population indirectness. Fasting morning cortisol levels used to define SAI are not specified. This study has been included in this review and also in the evidence review 4.1 for primary AI. Any data extracted has been included in both reviews.</p></blockquote><p>Two of the studies (Agha, 2004; Behan 2011; Behan 2016) excluded female subjects due to the potential effect of oestrogen status on corticosteroid-binding globulin (CBG) levels.</p><p>Due to heterogeneity in the interventions, comparators, and outcomes across the studies, it was not possible to generate meta-analyses.</p><p>No studies including children or people with tertiary AI were identified in this review.</p></div><div id="niceng243er7.s1.1.4.2"><h5>1.1.4.2. Excluded studies</h5><p>See the excluded studies list in <a href="#niceng243er7.appj">Appendix J</a>.</p></div></div><div id="niceng243er7.s1.1.5"><h4>1.1.5. Summary of studies included in the effectiveness evidence</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab2"><a href="/books/NBK609085/table/niceng243er7.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img" rid-ob="figobniceng243er7tab2"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab2"><a href="/books/NBK609085/table/niceng243er7.tab2/?report=objectonly" target="object" rid-ob="figobniceng243er7tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div><p>See <a href="#niceng243er7.appd">Appendix D</a> for full evidence tables.</p></div><div id="niceng243er7.s1.1.6"><h4>1.1.6. Summary of the effectiveness evidence</h4><p>See <a href="#niceng243er7.appf">Appendix F</a> for full GRADE tables.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab3"><a href="/books/NBK609085/table/niceng243er7.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img" rid-ob="figobniceng243er7tab3"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab3"><a href="/books/NBK609085/table/niceng243er7.tab3/?report=objectonly" target="object" rid-ob="figobniceng243er7tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: 5mg HC 2x daily vs 10 mg HC 2x daily. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab4"><a href="/books/NBK609085/table/niceng243er7.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img" rid-ob="figobniceng243er7tab4"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab4"><a href="/books/NBK609085/table/niceng243er7.tab4/?report=objectonly" target="object" rid-ob="figobniceng243er7tab4">Table 4</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Dose A (20 mg 0800 h, 10 mg 1600 h) vs Dose B (10 mg 0800 h and 1600 h) vs Dose C (10 mg 0800 h and 5 mg 1600 h) – SF-36 Outcomes. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab5"><a href="/books/NBK609085/table/niceng243er7.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img" rid-ob="figobniceng243er7tab5"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab5"><a href="/books/NBK609085/table/niceng243er7.tab5/?report=objectonly" target="object" rid-ob="figobniceng243er7tab5">Table 5</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Dose A (20 mg 0800 h, 10 mg 1600 h) vs Dose B (10 mg 0800 h and 1600 h) vs Dose C (10 mg 0800 h and 5 mg 1600 h) – Nottingham Health Profile (NHP) Outcomes. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab6"><a href="/books/NBK609085/table/niceng243er7.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img" rid-ob="figobniceng243er7tab6"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab6"><a href="/books/NBK609085/table/niceng243er7.tab6/?report=objectonly" target="object" rid-ob="figobniceng243er7tab6">Table 6</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Dose A (20 mg 0800 h, 10 mg 1600 h) vs Dose B (10 mg 0800 h and 1600 h) vs Dose C (10 mg 0800 h and 5 mg 1600 h) – Blood pressure (BP) outcomes. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab7"><a href="/books/NBK609085/table/niceng243er7.tab7/?report=objectonly" target="object" title="Table 7" class="img_link icnblk_img" rid-ob="figobniceng243er7tab7"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab7"><a href="/books/NBK609085/table/niceng243er7.tab7/?report=objectonly" target="object" rid-ob="figobniceng243er7tab7">Table 7</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Dose A [10mg/5mg HC] vs Dose B [10mg/5mg/5mg HC]. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab8"><a href="/books/NBK609085/table/niceng243er7.tab8/?report=objectonly" target="object" title="Table 8" class="img_link icnblk_img" rid-ob="figobniceng243er7tab8"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab8"><a href="/books/NBK609085/table/niceng243er7.tab8/?report=objectonly" target="object" rid-ob="figobniceng243er7tab8">Table 8</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Low dose HC (0.2-0.3 mg/kg) vs High dose HC (0.4-0.6 mg/kg). </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab9"><a href="/books/NBK609085/table/niceng243er7.tab9/?report=objectonly" target="object" title="Table 9" class="img_link icnblk_img" rid-ob="figobniceng243er7tab9"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab9"><a href="/books/NBK609085/table/niceng243er7.tab9/?report=objectonly" target="object" rid-ob="figobniceng243er7tab9">Table 9</a></h4><p class="float-caption no_bottom_margin">Modified-Release HC tablet vs Standard Glucocorticoid. </p></div></div></div><div id="niceng243er7.s1.1.7"><h4>1.1.7. Economic evidence</h4><div id="niceng243er7.s1.1.7.1"><h5>1.1.7.1. Included studies</h5><p>No health economic studies were included.</p></div><div id="niceng243er7.s1.1.7.2"><h5>1.1.7.2. Excluded studies</h5><p>No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.</p><p>See also the health economic study selection flow chart in 0.</p></div></div><div id="niceng243er7.s1.1.8"><h4>1.1.8. Unit costs</h4><p>Relevant unit costs are provided below to aid the consideration of cost-effectiveness. Unit costs for children are presented in <a href="/books/NBK609085/table/niceng243er7.tab10/?report=objectonly" target="object" rid-ob="figobniceng243er7tab10">Table 10</a> (combination hydrocortisone is a combination of standard release and Alkindi granules in capsules) and unit costs for adults are presented in <a href="/books/NBK609085/table/niceng243er7.tab11/?report=objectonly" target="object" rid-ob="figobniceng243er7tab11">Table 11</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab10"><a href="/books/NBK609085/table/niceng243er7.tab10/?report=objectonly" target="object" title="Table 10" class="img_link icnblk_img" rid-ob="figobniceng243er7tab10"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab10"><a href="/books/NBK609085/table/niceng243er7.tab10/?report=objectonly" target="object" rid-ob="figobniceng243er7tab10">Table 10</a></h4><p class="float-caption no_bottom_margin">Unit costs for children for the routine pharmacological management of secondary and tertiary adrenal insufficiency. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7tab11"><a href="/books/NBK609085/table/niceng243er7.tab11/?report=objectonly" target="object" title="Table 11" class="img_link icnblk_img" rid-ob="figobniceng243er7tab11"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.tab11"><a href="/books/NBK609085/table/niceng243er7.tab11/?report=objectonly" target="object" rid-ob="figobniceng243er7tab11">Table 11</a></h4><p class="float-caption no_bottom_margin">Unit costs for adults for the routine pharmacological management of secondary and tertiary adrenal insufficiency. </p></div></div></div></div><div id="niceng243er7.s1.2"><h3>1.2. The committee’s discussion and interpretation of the evidence</h3><div id="niceng243er7.s1.2.1"><h4>1.2.1. The outcomes that matter most</h4><p>The committee considered all outcomes listed in the protocol to be critical and of equal importance in decision-making. These outcomes included mortality, Health-related Quality of Life, complications of adrenal insufficiency, fatigue, incidence or complications of adrenal crisis, admission to hospital or ITU, length of hospital stay, treatment-related adverse events and activities of daily living.</p></div><div id="niceng243er7.s1.2.2"><h4>1.2.2. The quality of the evidence</h4><p>The clinical evidence for all outcomes was graded very low. This was largely due to imprecision and risk of bias. Imprecision arose from confidence intervals crossing one of MIDs and the risk of bias was mainly due to the lack of details on the randomisation process. Some studies were also downgraded for indirectness as the study population included only men.</p><p>All trials were cross-over RCTs that used oral glucocorticoid replacement therapies. Total daily doses ranged from 10 mg to 40 mg and were administered at different daily schedules. Outcomes were varied and included quality of life measures, cortisol levels and blood pressure. The variability in the interventions, comparators and outcomes meant that a meta-analysis of the data was not possible.</p><p>No studies including children or people with tertiary AI were identified in this review.</p></div><div id="niceng243er7.s1.2.3"><h4>1.2.3. Benefits and harms</h4><div id="niceng243er7.s1.2.3.1"><h5>Adults</h5><p>The committee noted that the evidence did not show any clinically important differences in metabolic measures (blood pressure and plasma sodium) when using 10 mg hydrocortisone (HC) twice daily compared to 5 mg twice daily. There was a clinically important difference in the peak cortisol levels at the higher dose. However, since there was no clinically important difference in the trough cortisol levels, the committee found this evidence inconclusive.</p><p>In discussing the evidence from a study comparing 3 different doses of hydrocortisone (Dose A [20mg/10mg] vs Dose B [10mg/10mg] vs Dose C [10mg/5mg], the committee noted that for most outcomes there were no clinically important differences between the treatment arms (SF-36 scores for mental health and all Nottingham Health Profile scores). For several outcomes where there were clinically important differences, the committee agreed that the evidence indicated that higher doses were better: for example, the SF-36 scores for role physical, bodily pain, vitality, social functioning, and role emotional. However, the committee acknowledged the very low quality rating of these outcomes and particularly the imprecision around the effect estimate which reduced the committees confidence in these findings. Ultimately, they did not take these benefits into account in their decision making.</p><p>In one study comparing Dose A (10/5mg HC) vs Dose B (10/5/5 mg HC) there was a clinically important benefit from treatment with Dose A (10/5 mg HC) compared to Dose B (10/5/5 mg HC) for the physical sum score of the SF-36 scale. Additionally, for the Stanford Sleepiness Scale outcomes, the evidence indicated a clinically important benefit from treatment with Dose A [10/5 mg] later in the day (18:00 and 22:00) compared to Dose B [10/5/5 mg]. However, the committee considered that these outcomes were downgraded twice for risk of bias and imprecision and consequently reduced their certainty in the results. There was also a clinically important harm for treatment with Dose A at 07:00 on the Stanford sleepiness scale, but at 12:00 and 15:00 there were no clinically important differences. Therefore, the committee did not use these outcomes to aid their decision making. There was no clinically important difference between the two treatments for the psychological sum score of the SF-36 scale, nor any difference for the BSI Global Severity Index or patient satisfaction with medication.</p><p>The committee noted that in a study comparing low-dose HC (0.2-0.3 mg/kg) vs. high-dose HC (0.4-0.6 mg/kg), there were no clinically important differences between the treatment arms for the majority of outcomes in this study: including metabolic outcomes (systolic/diastolic BP and BMI) and assessments of memory, attention and executive function. The only outcomes where clinically important differences were noted were social cognition, where the evidence indicated a clinically important harm from low-dose HC; and psychomotor speed, where the evidence indicated a clinically important benefit from low-dose HC. The committee noted that assessments of memory, attention, executive function, social cognition and psychomotor speed used in this study were based on a battery of tests as opposed to a single method of assessment. As a result, the committee found these assessments inconclusive as the results did not give a clear indication of which intervention was most beneficial.</p><p>In discussing the evidence from one study (Isidori 2018<a class="bibr" href="#niceng243er7.ref6" rid="niceng243er7.ref6"><sup>6</sup></a>) comparing once-daily modified-release hydrocortisone tablet to standard glucocorticoid therapy, the committee noted clinically important benefits for bodyweight, HbA1c %, AddiQOL and serious adverse events. A further two outcomes (infections in the last 6 months and BMI) just reached the threshold for a clinically important benefit of modified-release hydrocortisone tablets. Cholesterol showed no clinically important difference.</p><p>The committee acknowledged the benefits of modified-release hydrocortisone formulations but advised that they are not currently used as part of standard practice for the management of adrenal insufficiency in the UK, due to their high prices relative to standard oral hydrocortisone tablets. Furthermore, the committee noted that although there was some evidence of clinical benefit from the use of modified-release hydrocortisone tablets compared to standard glucocorticoid therapy, the magnitude of benefit was not significant enough to change standard practice.</p><p>Overall, the committee concluded that despite the disparities and the low certainty in the evidence, it mostly indicated that, for people with secondary adrenal insufficiency, total daily doses of hydrocortisone between 15-25 mg in divided doses were safe to use. This was also in line with their clinical expertise and reflected current practice. The committee was not able to determine the optimal dosage or timing of doses based on the evidence included in this review. They agreed for multiple daily doses, it would be usual to have the larger dose in the morning and the smaller in the evening, mimicking the normal diurnal rhythm of cortisol secretion. The committee also emphasised that as the maximum follow-up in these studies was 10 weeks, longer-term data would be needed to accurately assess the cumulative benefits and/or potential harms of daily treatment with hydrocortisone for people with secondary and tertiary adrenal insufficiency.</p><p>No clinical evidence was identified comparing prednisolone or dexamethasone to HC or to each other. Dexamethasone is not prescribed to adults in current practice due to the high risk of side effects such as cushingoid side effects. Prednisolone is known to have growth hampering effects. Therefore, it should only be used in people who have stopped growing and is a reasonable alternative to hydrocortisone for people who have difficulty taking hydrocortisone multiple times a day.</p></div><div id="niceng243er7.s1.2.3.2"><h5>Children and young people</h5><p>No evidence was identified in children. Therefore, the committee made recommendations based on their clinical experience and current practice. For children between 1 and 16 years old 8-10 mg/m2 of hydrocortisone in 3-4 divided doses would be prescribed. The committee agreed a reduced dose of prednisolone would be considered in children under age 16 who have reached final adult height when adherence to their replacement medication is a concern.</p><p>Based on clinical experience, the committee noted that adherence to glucocorticoid therapy is often an issue for patients with adrenal insufficiency since standard care typically involves 2 (BID) or 3 (TID) daily oral doses of hydrocortisone tablets. They noted that younger patients in particular younger adults, can often forget or choose to skip doses.</p><p>The committee suggested that a 1- or 2-dose regimen may likely have better acceptability among patients compared to a 3- to 4-dose regimen. Both prednisolone and modified release hydrocortisone tablets were considered alternatives due to their less frequent daily doses where adherence was a concern in young people. Prednisolone is only an option when the person has stopped growing. For modified release hydrocortsion tablets this was only an option if over 12 years and they have stopped growing. The committee noted the latter is off-label as it is only currently licensed in adults.</p><p>For infants under 1 year old a daily replacement dose of 8-10 mg/m2 hydrocortisone in 3- 4 equally divided doses would be prescribed. The committee did note that there would be a potential benefit in terms of adherence to therapy for a once-daily therapy compared to standard GC therapy.</p></div><div id="niceng243er7.s1.2.3.3"><h5>Tertiary AI</h5><p>No evidence was identified for tertiary AI. However, the committee agreed that although the underlying causes of tertiary and secondary adrenal Insufficiency are different, treatment is the same in both cases. The aim being, to adequately replace the missing cortisol through glucocorticoid replacement as cortisol is essential for life. Therefore, the committee agreed that the recommendations for tertiary adrenal insufficiency should be the same as those for secondary adrenal insufficiency.</p><p>The committee agreed that research evidence comparing different preparations of glucocorticoids (hydrocortisone, prednisolone and modified release hydrocortisone) for secondary and tertiary adrenal insufficiency is needed. This would determine the benefits of one pharmacological treatment over another in regard to improved clinical effectiveness. Therefore, the committee made a research recommendation (see <a href="#niceng243er7.appk">Appendix K</a>).</p></div></div><div id="niceng243er7.s1.2.4"><h4>1.2.4. Cost effectiveness and resource use</h4><p>No economic evaluations were identified for this review question; therefore, unit costs were presented to aid the committee’s consideration of cost-effectiveness.</p><p>For children, the costing was done using the unit costs of immediate-release tablets, alkindi granules and a combination of the two. The latter approach was to allow for smaller doses without splitting or dispersing tablets. The committee noted that current practice is variable in terms of which type of immediate-release hydrocortisone is used in children. The least expensive option was to use 10mg immediate-release hydrocortisone tablets, where one is used for each dose, with three to four a day needed. These tablets are either crushed and dispersed in water or split to make up the correct dose. Using alkindi granules alone or in combination with 2.5mg, 5mg or 10mg immediate-release hydrocortisone tablets is more expensive. The committee noted that dispersing tablets is not a licenced usage of immediate release hydrocortisone and therefore for young children who struggle to swallow tablets, the only licenced option is alkindi granules. In addition, the benefit of alkindi granules is more accurate dosing and ease of administration for parents and carers. It was also noted that no clinical evidence in children was identified comparing the alternative formulations, as such the committee did not specify which approach to take in the recommendation.</p><p>Similarly, to primary adrenal insufficiency, immediate release hydrocortisone was considered the first-choice glucocorticoid. The committee recommended prednisolone as an alternative glucocorticoid to immediate release hydrocortisone in those who have stopped growing and with adherence difficulties with immediate-release hydrocortisone. Due to the modified-release tablet preparation costing significantly more with similar efficacy, the committee recommended its use as an alternative glucocorticoid to be considered when immediate-release hydrocortisone and prednisolone are not suitable. Of note the latter only applied to adults and children over the age of 12 who had stopped growing.</p><p>The committee discussed the clinical evidence and costs presented and subsequently made recommendations reflective of current practice. Therefore, these recommendations will not result in a significant resource impact.</p></div><div id="niceng243er7.s1.2.5"><h4>1.2.5. Recommendations supported by this evidence review</h4><p>This evidence review supports recommendations 1.3.1 – 1.3.4 and the recommendation for research on the clinical and cost-effectiveness of pharmacological treatments for the routine management of secondary and tertiary adrenal insufficiency.</p></div></div></div><div id="niceng243er7.rl.r1"><h2 id="_niceng243er7_rl_r1_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="niceng243er7.ref1">Agha
|
|
A, Liew
|
|
A, Finucane
|
|
F, Baker
|
|
L, O’Kelly
|
|
P, Tormey
|
|
W
|
|
et al. Conventional glucocorticoid replacement overtreats adult hypopituitary patients with partial ACTH deficiency. Clinical Endocrinology. 2004; 60(6):688–693
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15163331" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15163331</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="niceng243er7.ref2">Behan
|
|
LA, Carmody
|
|
D, Rogers
|
|
B, Hannon
|
|
MJ, Davenport
|
|
C, Tormey
|
|
W
|
|
et al. Low-dose hydrocortisone replacement is associated with improved arterial stiffness index and blood pressure dynamics in severely adrenocorticotrophin-deficient hypopituitary male patients. European Journal of Endocrinology. 2016; 174(6):791–799
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27025241" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27025241</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="niceng243er7.ref3">Behan
|
|
LA, Rogers
|
|
B, Hannon
|
|
MJ, O’Kelly
|
|
P, Tormey
|
|
W, Smith
|
|
D
|
|
et al. Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients. Clinical Endocrinology. 2011; 75(4):505–513
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21521342" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21521342</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="niceng243er7.ref4">Benson
|
|
S, Neumann
|
|
P, Unger
|
|
N, Schedlowski
|
|
M, Mann
|
|
K, Elsenbruch
|
|
S
|
|
et al. Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency. European Journal of Endocrinology. 2012; 167(5):679–685
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22930487" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22930487</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="niceng243er7.ref5">BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National Formulary. 2023. Available from: <a href="https://bnf.nice.org.uk/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://bnf<wbr style="display:inline-block"></wbr>​.nice.org.uk/</a> Last accessed: 05/11/2023.</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="niceng243er7.ref6">Isidori
|
|
AM, Venneri
|
|
MA, Graziadio
|
|
C, Simeoli
|
|
C, Fiore
|
|
D, Hasenmajer
|
|
V
|
|
et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2018; 6(3):173–185
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29229498" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29229498</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="niceng243er7.ref7">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.nice.org<wbr style="display:inline-block"></wbr>​.uk/process/pmg20/chapter/introduction</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/26677490" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26677490</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="niceng243er7.ref8">Werumeus Buning
|
|
J, Brummelman
|
|
P, Koerts
|
|
J, Dullaart
|
|
RP, van den Berg
|
|
G, van der Klauw
|
|
MM
|
|
et al. The effects of two different doses of hydrocortisone on cognition in patients with secondary adrenal insufficiency--results from a randomized controlled trial. Psychoneuroendocrinology. 2015; 55:36–47
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25705800" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25705800</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="niceng243er7.ref9">Werumeus Buning
|
|
J, van Faassen
|
|
M, Brummelman
|
|
P, Dullaart
|
|
RP, van den Berg
|
|
G, van der Klauw
|
|
MM
|
|
et al. Effects of hydrocortisone on the regulation of blood pressure: Results from a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism. 2016; 101(10):3691–3699
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27490921" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27490921</span></a>]</div></dd></dl></dl></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng243er7.appa"><h3>Appendix A. Review protocols</h3><p id="niceng243er7.appa.et1"><a href="/books/NBK609085/bin/niceng243er7-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">A.1. Review protocol for 4.2: pharmacological management of secondary and tertiary adrenal hyperplasia</a><span class="small"> (PDF, 216K)</span></p><p id="niceng243er7.appa.et2"><a href="/books/NBK609085/bin/niceng243er7-appa-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">A.2. Health economic review protocol</a><span class="small"> (PDF, 137K)</span></p></div><div id="niceng243er7.appb"><h3>Appendix B. Literature search strategies</h3><p>The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.<a class="bibr" href="#niceng243er7.ref7" rid="niceng243er7.ref7"><sup>7</sup></a></p><p>For more information, please see the <a href="/books/NBK609085/bin/NG243-Methods.pdf">Methodology</a> review published as part of the accompanying documents for this guideline.</p><p id="niceng243er7.appb.et1"><a href="/books/NBK609085/bin/niceng243er7-appb-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">B.1. Clinical search literature search strategy</a><span class="small"> (PDF, 195K)</span></p><p id="niceng243er7.appb.et2"><a href="/books/NBK609085/bin/niceng243er7-appb-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">B.2. Health Economics literature search strategy</a><span class="small"> (PDF, 200K)</span></p></div><div id="niceng243er7.appc"><h3>Appendix C. Effectiveness evidence study selection</h3><p id="niceng243er7.appc.et1"><a href="/books/NBK609085/bin/niceng243er7-appc-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 1. Flow chart of clinical study selection for the review of routine pharmacological management of secondary and tertiary AI</a><span class="small"> (PDF, 120K)</span></p></div><div id="niceng243er7.appd"><h3>Appendix D. Effectiveness evidence</h3><p id="niceng243er7.appd.et1"><a href="/books/NBK609085/bin/niceng243er7-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (371K)</span></p></div><div id="niceng243er7.appe"><h3>Appendix E. Forest plots</h3><p id="niceng243er7.appe.et1"><a href="/books/NBK609085/bin/niceng243er7-appe-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">E.1.1.1. Comparison 1: 5mg HC 2x daily vs 10 mg HC 2x daily</a><span class="small"> (PDF, 214K)</span></p><p id="niceng243er7.appe.et2"><a href="/books/NBK609085/bin/niceng243er7-appe-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">E.1.1.2. Comparison 2: Dose A [20mg/10mg] vs Dose B [10mg/10mg] vs Dose C [10mg/5mg] – SF-36 Outcomes</a><span class="small"> (PDF, 377K)</span></p><p id="niceng243er7.appe.et3"><a href="/books/NBK609085/bin/niceng243er7-appe-et3.pdf" class="bk_dwnld_icn bk_dwnld_pdf">E.1.1.3. Comparison 3: Dose A [20mg/10mg] vs Dose B [10mg/10mg] vs Dose C [10mg/5mg] – Nottingham health profile (NHP) Outcomes</a><span class="small"> (PDF, 390K)</span></p><p id="niceng243er7.appe.et4"><a href="/books/NBK609085/bin/niceng243er7-appe-et4.pdf" class="bk_dwnld_icn bk_dwnld_pdf">E.1.1.4. Comparison 4: Dose A [20mg/10mg] vs Dose B [10mg/10mg] vs Dose C [10mg/5mg] – Blood Pressure Outcomes</a><span class="small"> (PDF, 323K)</span></p><p id="niceng243er7.appe.et5"><a href="/books/NBK609085/bin/niceng243er7-appe-et5.pdf" class="bk_dwnld_icn bk_dwnld_pdf">E.1.1.5. Comparison 5: Dose A [10mg/5mg HC] vs Dose B [10mg/5mg/5mg HC]</a><span class="small"> (PDF, 350K)</span></p><p id="niceng243er7.appe.et6"><a href="/books/NBK609085/bin/niceng243er7-appe-et6.pdf" class="bk_dwnld_icn bk_dwnld_pdf">E.1.1.6. Comparison 6: Low dose HC [0.2-0.3 mg/kg] vs High dose HC [0.4-0.6 mg/kg]</a><span class="small"> (PDF, 590K)</span></p><p id="niceng243er7.appe.et7"><a href="/books/NBK609085/bin/niceng243er7-appe-et7.pdf" class="bk_dwnld_icn bk_dwnld_pdf">E.1.1.7. Modified-Release HC tablet vs Standard Glucocorticoid [Isidori 2018]</a><span class="small"> (PDF, 300K)</span></p></div><div id="niceng243er7.appf"><h3>Appendix F. GRADE tables</h3><p id="niceng243er7.appf.et1"><a href="/books/NBK609085/bin/niceng243er7-appf-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 16. Clinical evidence profile: 5mg HC 2x daily vs 10 mg HC 2x daily</a><span class="small"> (PDF, 146K)</span></p><p id="niceng243er7.appf.et2"><a href="/books/NBK609085/bin/niceng243er7-appf-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 17. Clinical evidence profile: Dose A (20 mg 0800 h, 10 mg 1600 h) vs Dose B (10 mg 0800 h and 1600 h) vs Dose C (10 mg 0800 h and 5 mg 1600 h) for secondary and tertiary adrenal insufficiency [SF-36 Outcomes]</a><span class="small"> (PDF, 289K)</span></p><p id="niceng243er7.appf.et3"><a href="/books/NBK609085/bin/niceng243er7-appf-et3.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 18. Clinical evidence profile: Dose A (20 mg 0800 h, 10 mg 1600 h) vs Dose B (10 mg 0800 h and 1600 h) vs Dose C (10 mg 0800 h and 5 mg 1600 h) for secondary and tertiary adrenal insufficiency [Blood Pressure Outcomes]</a><span class="small"> (PDF, 174K)</span></p><p id="niceng243er7.appf.et4"><a href="/books/NBK609085/bin/niceng243er7-appf-et4.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 19. Clinical evidence profile: Dose A [10mg/5mg HC] vs Dose B [10mg/5mg/5mg HC]</a><span class="small"> (PDF, 166K)</span></p><p id="niceng243er7.appf.et5"><a href="/books/NBK609085/bin/niceng243er7-appf-et5.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 20. Clinical evidence profile: Low dose HC [0.2-0.3 mg/kg] vs High dose HC [0.4-0.6mg/kg]</a><span class="small"> (PDF, 167K)</span></p><p id="niceng243er7.appf.et6"><a href="/books/NBK609085/bin/niceng243er7-appf-et6.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 21. Modified-Release HC tablet vs Standard Glucocorticoid</a><span class="small"> (PDF, 163K)</span></p></div><div id="niceng243er7.appg"><h3>Appendix G. Economic evidence study selection</h3><p id="niceng243er7.appg.et1"><a href="/books/NBK609085/bin/niceng243er7-appg-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (227K)</span></p></div><div id="niceng243er7.apph"><h3>Appendix H. Economic evidence tables</h3><p>None</p></div><div id="niceng243er7.appi"><h3>Appendix I. Health economic model</h3><p>No health economic model undertaken.</p></div><div id="niceng243er7.appj"><h3>Appendix J. Excluded studies</h3><div id="niceng243er7.appj.s1"><h4>J.1. Clinical studies</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng243er7appjtab1"><a href="/books/NBK609085/table/niceng243er7.appj.tab1/?report=objectonly" target="object" title="Table 22" class="img_link icnblk_img" rid-ob="figobniceng243er7appjtab1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng243er7.appj.tab1"><a href="/books/NBK609085/table/niceng243er7.appj.tab1/?report=objectonly" target="object" rid-ob="figobniceng243er7appjtab1">Table 22</a></h4><p class="float-caption no_bottom_margin">Studies excluded from the clinical review. </p></div></div></div><div id="niceng243er7.appj.s2"><h4>J.2. Health Economic studies</h4><p>None.</p></div></div><div id="niceng243er7.appk"><h3>Appendix K. Recommendation for research</h3><p id="niceng243er7.appk.et1"><a href="/books/NBK609085/bin/niceng243er7-appk-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">K.1. Research question</a><span class="small"> (PDF, 150K)</span></p></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Evidence review underpinning recommendations 1.3.1 to 1.3.4 and recommendation for research 4 in the NICE guideline</p><p>This evidence review was developed by NICE</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="https://www.gov.wales/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2024.</div><div class="small"><span class="label">Bookshelf ID: NBK609085</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39541484" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">39541484</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng243er7tab1"><div id="niceng243er7.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng243er7.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng243er7.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">People with adrenal insufficiency (secondary or tertiary) who are diagnosed or suspected of having an adrenal crisis including the following groups:
|
|
<ul><li class="half_rhythm"><div>Adults (aged ≥16 years).</div></li><li class="half_rhythm"><div>Children aged ≥5 up to 16 years.</div></li><li class="half_rhythm"><div>Infants aged 1-5 years (because of more frequent dosing).</div></li><li class="half_rhythm"><div>Infants aged <1 year including neonates.</div></li></ul></td></tr><tr><th id="hd_b_niceng243er7.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention(s)</th><td headers="hd_b_niceng243er7.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Glucocorticoids:</b>
|
|
<ul><li class="half_rhythm"><div>Hydrocortisone including:
|
|
<ul class="circle"><li class="half_rhythm"><div>Oral</div></li><li class="half_rhythm"><div>Modified release hydrocortisone</div></li><li class="half_rhythm"><div>Injected forms (sub cut and iv)</div></li></ul></div></li><li class="half_rhythm"><div>Prednisolone</div></li><li class="half_rhythm"><div>Dexamethasone</div></li></ul>
|
|
*Be aware some are not licensed for children</p>
|
|
<p>Note: weight-based regimens should also be included</p>
|
|
<p><b>Exclusions:</b>
|
|
<ul><li class="half_rhythm"><div>Hydrocortisone acetate</div></li><li class="half_rhythm"><div>Long-acting methylprednisolone</div></li><li class="half_rhythm"><div>Prednisone (not used in the UK)</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng243er7.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison(s)</th><td headers="hd_b_niceng243er7.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>For glucocorticoids:</b>
|
|
</p>
|
|
<p>Glucocorticoids compared to each other including different doses, routes of administration and preparations (e.g., modified release compared to standard, crushed tablets compared to whole tablets or oral suspensions)</p>
|
|
<p>
|
|
<b>For all:</b>
|
|
</p>
|
|
<p>Comparisons to standard care as defined by authors.</p>
|
|
</td></tr><tr><th id="hd_b_niceng243er7.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_niceng243er7.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All outcomes are considered equally important for decision making and therefore have all been rated as critical:
|
|
<ul><li class="half_rhythm"><div class="half_rhythm">Mortality</div></li><li class="half_rhythm"><div class="half_rhythm">Health-related quality of life, for example EQ-5D, SF-36</div></li><li class="half_rhythm"><div class="half_rhythm">Complications of adrenal insufficiency</div><div class="half_rhythm">Fatigue as measured using specific fatigue scales such as National Fatigue Index (NFI), fatigue Severity Scale (FSS)</div></li><li class="half_rhythm"><div class="half_rhythm">Incidence of adrenal crisis (as defined by authors)</div></li><li class="half_rhythm"><div class="half_rhythm">Complications of adrenal crisis</div></li><li class="half_rhythm"><div class="half_rhythm">Admission to hospital and/or ITU</div></li><li class="half_rhythm"><div class="half_rhythm">Readmission to hospital</div></li><li class="half_rhythm"><div class="half_rhythm">Length of hospital stay.</div></li><li class="half_rhythm"><div class="half_rhythm">Treatment-related adverse events</div></li><li class="half_rhythm"><div class="half_rhythm">Activities of daily living</div></li></ul>
|
|
<b>Follow up:</b></p>
|
|
<p>Any time point as this will be different for different variables. Most will be short term (within 30 days) except for weight or growth-related outcomes, QoL and activities of daily living.</p>
|
|
<p>We will prioritise data from similar timepoints in order to increase the possibility of conducting a meta-analysis (if appropriate)</p>
|
|
</td></tr><tr><th id="hd_b_niceng243er7.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng243er7.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Systematic reviews of RCTs and RCTs will be considered for inclusion.</p>
|
|
<p>Cross-over trials will also be considered for inclusion regardless of washout period as it is unsafe for patients to be completely free of background medication especially glucocorticoids.</p>
|
|
<p>If insufficient RCT evidence is available, a search for non-randomised studies will be conducted. Studies will only be considered for inclusion if they have conducted a multivariate analysis adjusting for at least 3-4 of the following key confounders: age, sex, weight / BMI, smoking, Type 1 diabetes, thyroid disease.</p>
|
|
<p>Published NMAs and IPDs will be considered for inclusion.</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng243er7tab2"><div id="niceng243er7.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng243er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng243er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention and comparison</th><th id="hd_h_niceng243er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng243er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Relevant outcomes</th><th id="hd_h_niceng243er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng243er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Agha 2004<a class="bibr" href="#niceng243er7.ref1" rid="niceng243er7.ref1"><sup>1</sup></a></p>
|
|
<p>Crossover RCT</p>
|
|
<p>Conducted in Ireland</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Group 1: Conventional full-dose hydrocortisone - 10mg twice daily</p>
|
|
<p>Group 2: Half dose hydrocortisone - 5mg twice daily</p>
|
|
<p>Follow-up: 1 weeks</p>
|
|
<p>After 1 week, patients switched groups</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=10 male adults with partial ACTH deficiency, defined as a fasting 08·00 h total serum cortisol exceeding 200 nmol/l with a stimulated peak value of less than 500 nmol/l</p>
|
|
<p>Mean age 43.9 (range 23 -60 years)</p>
|
|
<p>Female subjects were excluded because of the potential effect of oestrogen status on corticosteroid-binding globulin (CBG) levels.</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Peak cortisol</p>
|
|
<p>Trough cortisol</p>
|
|
<p>Systolic BP</p>
|
|
<p>Diastolic BP</p>
|
|
<p>Plasma sodium</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Behan 2011<a class="bibr" href="#niceng243er7.ref3" rid="niceng243er7.ref3"><sup>3</sup></a></p>
|
|
<p>Crossover RCT</p>
|
|
<p>Conducted in Ireland</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Oral hydrocortisone administered in the following dose regimens: Dose A (20 mg 0800 h, 10 mg 1600 h), Dose B (10 mg 0800h and 1600h), Dose C (10 mg 0800 h and 5 mg 1600 h) for 6 weeks of each dose regimen</p>
|
|
<p>Follow-up: 6 weeks</p>
|
|
<p>After 6 weeks, patients switched groups.</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=10 male adults with severe ACTH deficiency, defined by a fasting morning total serum cortisol concentration <100 nmol/l and a stimulated peak cortisol in response to insulin-induced hypoglycaemia of <400 nmol/l</p>
|
|
<p>Mean age 46 (range 26-65 years)</p>
|
|
<p>Female subjects were excluded because of the potential effect of oestrogen status on corticosteroid-binding globulin (CBG) levels.</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>SF-36 scores</p>
|
|
<p>Nottingham Health Profile (NHP) scores</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Behan 2016<a class="bibr" href="#niceng243er7.ref2" rid="niceng243er7.ref2"><sup>2</sup></a></p>
|
|
<p>Crossover RCT</p>
|
|
<p>Conducted in Ireland</p>
|
|
<p>*Secondary publication of Behan 2011*</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>See above</i>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>See above</i>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Systolic BP (24-hr ambulatory)</p>
|
|
<p>Diastolic BP (24-hr ambulatory)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Benson 2012<a class="bibr" href="#niceng243er7.ref4" rid="niceng243er7.ref4"><sup>4</sup></a></td><td headers="hd_h_niceng243er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Oral hydrocortisone administered in the following dose regimens:</p>
|
|
<p>Dose A: 10mg at 0700, 5mg at 1500</p>
|
|
<p>Dose B: 10mg at 0700, 5mg at 1200, 5mg at 1800</p>
|
|
<p>Follow-up:</p>
|
|
<p>After 6 weeks, patients switched groups</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>N=18 patients with secondary adrenal insufficiency, defined as peak cortisol =< 450 nmol/L</p>
|
|
<p>Mean age 52 years (SD 10.3)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>SF-36 score. BSI Global Severity Index</p>
|
|
<p>Stanford Sleepiness Score</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Isidori 2018<a class="bibr" href="#niceng243er7.ref6" rid="niceng243er7.ref6"><sup>6</sup></a></p>
|
|
<p>Normal RCT</p>
|
|
<p>Single-blind</p>
|
|
<p>Conducted in</p>
|
|
<p>Italy</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention: Once-daily (MR-HC). Patients were instructed to take the dose on waking. Patients previously on multiple doses of hydrocortisone a day received the same total daily dose, whereas patients previously on cortisone received 0·8 mg of hydrocortisone per 1 mg of cortisone. Intermediate doses were rounded up to the nearest 5 mg (e.g. 22·5 mg to 25·0 mg) to avoid any potential dangerous reduction in total daily dose. Dose of MR-HC was equivalent to standard care.</p>
|
|
<p>Comparison: Standard care (continue standard glucocorticoid therapy)</p>
|
|
<p>Follow-up: 24 weeks</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89 adults with primary AI (n=44 Addison’s disease) or secondary (n=45) Mean age 48, IQR 43-54</td><td headers="hd_h_niceng243er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>BMI</p>
|
|
<p>Bodyweight</p>
|
|
<p>HbA1c</p>
|
|
<p>AddiQoL</p>
|
|
<p>Infections (flu or flu-like events in 6 months)</p>
|
|
<p>Total cholesterol</p>
|
|
<p>Serious adverse</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patients were on a stable hydrocortisone dose (for at least 3 months before entering the study), which was kept constant throughout the study. Prior to study enrolment, baseline HC equivalent dose adjusted for body surface area (mg/m2 per day) in the intervention group was 16 (95%CI 14-18) and 18 (95%CI 15-21) in the control group.</p>
|
|
<p>Study included a mixed population of primary and secondary AI</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Wermeus Buning 2015<a class="bibr" href="#niceng243er7.ref8" rid="niceng243er7.ref8"><sup>8</sup></a></p>
|
|
<p>Crossover RCT</p>
|
|
<p>Conducted in the Netherlands</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Oral hydrocortisone administered TID in the following dose regimens:</p>
|
|
<p>Low dose: 0.2-0.3mg/kg body weight. Total daily HC doses ranged from 15mg (for people 50-74kg), 17.5 mg (75-84kg) to 20mg (85-100kg).</p>
|
|
<p>High dose: 0.4-0.6mg/kg body weight. Total daily HC doses ranged from 30mg (for people 50-74kg), 35 mg (75-84kg) to 40mg (85-100kg).</p>
|
|
<p>Follow-up: 10 weeks</p>
|
|
<p>After 10 weeks, patients switched groups</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>N=47 people with secondary adrenal insufficiency (SAI) who receive glucocorticoid replacement therapy</p>
|
|
<p>Median age (IQR): 55 (43-61)</p>
|
|
<p>38% female</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Numbers of patients showing impaired scores in the following dimensions: Immediate memory, Short-term memory, Delayed memory, Recognition, Divided attention, Visual scanning, Fluency Working memory, Cognitive flexibility, Social cognition, Psychomotor speed</td><td headers="hd_h_niceng243er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Wermeus Buning 2016<a class="bibr" href="#niceng243er7.ref9" rid="niceng243er7.ref9"><sup>9</sup></a></p>
|
|
<p>Secondary publication of Wermeus Buning 2015</p>
|
|
<p>
|
|
<i>See above</i>
|
|
</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>See above</i>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>See above</i>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Systolic BP</p>
|
|
<p>Diastolic BP</p>
|
|
<p>BMI</p>
|
|
<p>Plasma sodium</p>
|
|
</td><td headers="hd_h_niceng243er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng243er7tab3"><div id="niceng243er7.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Clinical evidence summary: 5mg HC 2x daily vs 10 mg HC 2x daily</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng243er7.tab3_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab3_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng243er7.tab3_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab3_1_1_1_2" style="text-align:center;vertical-align:middle;">№ of participants (studies) Follow-up</th><th id="hd_h_niceng243er7.tab3_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab3_1_1_1_3" style="text-align:center;vertical-align:middle;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng243er7.tab3_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab3_1_1_1_4" style="text-align:center;vertical-align:middle;">Relative effect (95% CI)</th><th id="hd_h_niceng243er7.tab3_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng243er7.tab3_1_1_1_5" id="hd_h_niceng243er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with 10 mg 2x daily</th><th headers="hd_h_niceng243er7.tab3_1_1_1_5" id="hd_h_niceng243er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with 5mg 2x daily</th></tr></thead><tbody><tr><td headers="hd_h_niceng243er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Peak cortisol (nmol/L)</b>
|
|
</p>
|
|
<p>follow-up: 1 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab3_1_1_1_5 hd_h_niceng243er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean peak cortisol (nmol/L) was <b>508.6</b> nmol/L</td><td headers="hd_h_niceng243er7.tab3_1_1_1_5 hd_h_niceng243er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>84.2 nmol/L lower</b></p>
|
|
<p>(163.12 lower to 5.28 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Trough cortisol (nmol/L)</b>
|
|
</p>
|
|
<p>follow-up: 1 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab3_1_1_1_5 hd_h_niceng243er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean trough cortisol (nmol/L) was <b>149.8</b> nmol/L</td><td headers="hd_h_niceng243er7.tab3_1_1_1_5 hd_h_niceng243er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>15.8 nmol/L higher</b></p>
|
|
<p>(38.06 lower to 69.66 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Systolic BP (mmHg)</b>
|
|
</p>
|
|
<p>follow-up: 1 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab3_1_1_1_5 hd_h_niceng243er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean systolic BP (mmHg) was <b>129.5</b> mmHg</td><td headers="hd_h_niceng243er7.tab3_1_1_1_5 hd_h_niceng243er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>4.8 mmHg higher</b></p>
|
|
<p>(7.03 lower to 16.63 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Diastolic BP (mmHg)</b>
|
|
</p>
|
|
<p>follow-up: 1 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab3_1_1_1_5 hd_h_niceng243er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean diastolic BP (mmHg) was <b>83.4</b> mmHg</td><td headers="hd_h_niceng243er7.tab3_1_1_1_5 hd_h_niceng243er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.3 mmHg higher</b></p>
|
|
<p>(8.25 lower to 8.85 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Plasma sodium (nmol/L)</b>
|
|
</p>
|
|
<p>follow-up: 1 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>g</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab3_1_1_1_5 hd_h_niceng243er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean plasma sodium (nmol/L) was <b>140.5</b> mmol/L</td><td headers="hd_h_niceng243er7.tab3_1_1_1_5 hd_h_niceng243er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.3 mmol/L lower</b></p>
|
|
<p>(1.79 lower to 1.19 higher)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng243er7.tab3_1"><p class="no_margin">Downgraded by 2 increment due to very high risk of bias arising from the randomisation process</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng243er7.tab3_2"><p class="no_margin">Downgraded by 1 increment as population includes males only [Female subjects were excluded because of the potential effect of oestrogen status on corticosteroid-binding globulin (CBG) levels]</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng243er7.tab3_3"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 43)</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng243er7.tab3_4"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 24.55)</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng243er7.tab3_5"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 6.2)</p></div></dd></dl><dl class="bkr_refwrap"><dt>f</dt><dd><div id="niceng243er7.tab3_6"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 4.35)</p></div></dd></dl><dl class="bkr_refwrap"><dt>g</dt><dd><div id="niceng243er7.tab3_7"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 0.85)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng243er7tab4"><div id="niceng243er7.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">Clinical evidence summary: Dose A (20 mg 0800 h, 10 mg 1600 h) vs Dose B (10 mg 0800 h and 1600 h) vs Dose C (10 mg 0800 h and 5 mg 1600 h) – SF-36 Outcomes</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab4_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab4_1_1_1_2" style="text-align:center;vertical-align:middle;">№ of participants (studies) Follow-up</th><th id="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab4_1_1_1_3" style="text-align:center;vertical-align:middle;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab4_1_1_1_4" style="text-align:center;vertical-align:middle;">Relative effect (95% CI)</th><th id="hd_h_niceng243er7.tab4_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng243er7.tab4_1_1_1_5" id="hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with comparator</th><th headers="hd_h_niceng243er7.tab4_1_1_1_5" id="hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with intervention</th></tr></thead><tbody><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Physical functioning - A vs B</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Physical functioning - A vs B was <b>79.5</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>9 points higher</b></p>
|
|
<p>(9.74 lower to 27.74 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Physical functioning - A vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Physical functioning - A vs C was <b>80.5</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>8 points higher</b></p>
|
|
<p>(10.99 lower to 26.99 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Physical functioning - B vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Physical functioning - B vs C was <b>80.5</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>1 points lower</b></p>
|
|
<p>(22.26 lower to 20.26 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Role Physical – A vs B</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Role Physical - A vs B was <b>62.5</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>15 points higher</b></p>
|
|
<p>(17.36 lower to 47.36 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Role Physical - A vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Role Physical - A vs C was <b>55</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>22.5 points higher</b></p>
|
|
<p>(14.15 lower to 59.15 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Role Physical - B vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Role Physical - B vs C was <b>55</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>7.5 points higher</b></p>
|
|
<p>(28.29 lower to 43.29 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Bodily pain - A vs B</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Bodily pain - A vs B was <b>82.5</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2.6 points higher</b></p>
|
|
<p>(16.67 lower to 21.87 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Bodily pain - A vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Bodily pain - A vs C was <b>76.5</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>8.6 points higher</b></p>
|
|
<p>(10.2 lower to 27.4 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Bodily pain - B vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Bodily pain - B vs C was <b>76.5</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>6 points higher</b></p>
|
|
<p>(14.43 lower to 26.43 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - General health - A vs B</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - General health - A vs B was <b>61.8</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>1 points higher</b></p>
|
|
<p>(13.06 lower to 15.06 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - General health - A vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - General health - A vs C was <b>59.8</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>3 points higher</b></p>
|
|
<p>(11.81 lower to 17.81 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - General health - B vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - General health - B vs C was <b>59.8</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2 points higher</b></p>
|
|
<p>(10.3 lower to 14.3 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Vitality - A vs B</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Vitality - A vs B was <b>47.5</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>15 points higher</b></p>
|
|
<p>(6.14 lower to 36.14 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Vitality - A vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Vitality - A vs C was <b>44</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>18.5 points higher</b></p>
|
|
<p>(3.15 lower to 40.15 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Vitality - B vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Vitality - B vs C was <b>44</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>3.5 points higher</b></p>
|
|
<p>(17.46 lower to 24.46 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Social functioning - A vs B</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Social functioning - A vs B was <b>92.5</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2.5 points lower</b></p>
|
|
<p>(16.11 lower to 11.11 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Social functioning - A vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Social functioning - A vs C was <b>85</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>7.5 points higher</b></p>
|
|
<p>(6.61 lower to 21.61 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Social functioning - B vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Social functioning - B vs C was <b>85</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>7.5 points higher</b></p>
|
|
<p>(6.61 lower to 21.61 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Role emotional - A vs B</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Role emotional - A vs B was <b>66.6</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>16.7 points higher</b></p>
|
|
<p>(17.35 lower to 50.75 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Role emotional - A vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Role emotional - A vs C was <b>73.3</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>10 points higher</b></p>
|
|
<p>(23.77 lower to 43.77 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Role emotional - B vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Role emotional - B vs C was <b>73.3</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>6.7 points lower</b></p>
|
|
<p>(42.81 lower to 29.41 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Mental health - A vs B</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Mental health - A vs B was <b>80</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.4 points lower</b></p>
|
|
<p>(16.49 lower to 15.69 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Mental health - A vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Mental health - A vs C was <b>80</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.4 points lower</b></p>
|
|
<p>(15.83 lower to 15.03 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF36 - Mental health - B vs C</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF36 - Mental health - B vs C was <b>80</b> points</td><td headers="hd_h_niceng243er7.tab4_1_1_1_5 hd_h_niceng243er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0 points</b></p>
|
|
<p>(15.92 lower to 15.92 higher)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng243er7.tab4_1"><p class="no_margin">Downgraded by 2 increments due to very serious risk of bias: Study authors do not provide necessary details around recruitment and randomisation so outcomes are at very high risk of selection bias..</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng243er7.tab4_2"><p class="no_margin">Downgraded by 1 increment as population includes males only [Female subjects were excluded because of the potential effect of oestrogen status on corticosteroid-binding globulin (CBG) levels]</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng243er7.tab4_3"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 3)</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng243er7.tab4_4"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 2)</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng243er7.tab4_5"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 4)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng243er7tab5"><div id="niceng243er7.tab5" class="table"><h3><span class="label">Table 5</span><span class="title">Clinical evidence summary: Dose A (20 mg 0800 h, 10 mg 1600 h) vs Dose B (10 mg 0800 h and 1600 h) vs Dose C (10 mg 0800 h and 5 mg 1600 h) – Nottingham Health Profile (NHP) Outcomes</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab5_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab5_1_1_1_2" style="text-align:center;vertical-align:middle;">№ of participants (studies) Follow-up</th><th id="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab5_1_1_1_3" style="text-align:center;vertical-align:middle;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab5_1_1_1_4" style="text-align:center;vertical-align:middle;">Relative effect (95% CI)</th><th id="hd_h_niceng243er7.tab5_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng243er7.tab5_1_1_1_5" id="hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with comparator</th><th headers="hd_h_niceng243er7.tab5_1_1_1_5" id="hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with intervention</th></tr></thead><tbody><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Energy level - A vs B</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Energy level - A vs B was <b>35.1</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>1.2 points higher</b></p>
|
|
<p>(36.54 lower to 38.94 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Energy level - A vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Energy level - A vs C was <b>41.3</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>5 points lower</b></p>
|
|
<p>(40.56 lower to 30.56 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Energy level - B vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Energy level - B vs C was <b>41.3</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>6.2 points lower</b></p>
|
|
<p>(41.25 lower to 28.85 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Pain - A vs B</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Pain - A vs B was <b>7</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>1.1 points higher</b></p>
|
|
<p>(15.72 lower to 17.92 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Pain - A vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Pain - A vs C was <b>10.6</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2.5 points lower</b></p>
|
|
<p>(21.7 lower to 16.7 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Pain - B vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Pain - B vs C was <b>10.6</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>3.6 points lower</b></p>
|
|
<p>(20.11 lower to 12.91 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Emotional reaction - A vs B</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>g</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Emotional reaction - A vs B was <b>7.3</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>1.2 points higher</b></p>
|
|
<p>(10.33 lower to 12.73 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Emotional reaction - A vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>h</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Emotional reaction - A vs C was <b>8.6</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.1 points lower</b></p>
|
|
<p>(12.47 lower to 12.27 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Emotional reaction - B vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>h</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Emotional reaction - B vs C was <b>8.6</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>1.3 points lower</b></p>
|
|
<p>(15.6 lower to 13 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Sleep - A vs B</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>i</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Sleep - A vs B was <b>15.3</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>5.4 points higher</b></p>
|
|
<p>(18.3 lower to 29.1 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Sleep - A vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>j</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Sleep - A vs C was <b>10.9</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>9.8 points higher</b></p>
|
|
<p>(8.29 lower to 27.89 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Sleep - B vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>k</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Sleep - B vs C was <b>10.9</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>4.4 points higher</b></p>
|
|
<p>(17.4 lower to 26.2 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Social isolation - A vs B</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>l</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Social isolation - A vs B was <b>7.5</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>1 points higher</b></p>
|
|
<p>(14.2 lower to 16.2 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Social isolation - A vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>m</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Social isolation - A vs C was <b>0</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0 points</b></p>
|
|
<p>(0 to 0)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Social isolation - B vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>m</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Social isolation - B vs C was <b>0</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0 points</b></p>
|
|
<p>(0 to 0)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Physical abilities - A vs B</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>n</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Physical abilities - A vs B was <b>13.1</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>4.2 points lower</b></p>
|
|
<p>(20.78 lower to 12.38 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Physical abilities - A vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>o</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Physical abilities - A vs C was <b>14.4</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>5.5 points lower</b></p>
|
|
<p>(21.43 lower to 10.43 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>NHP - Physical abilities - B vs C</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>o</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean NHP - Physical abilities - B vs C was <b>14.4</b> points</td><td headers="hd_h_niceng243er7.tab5_1_1_1_5 hd_h_niceng243er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>1.3 points lower</b></p>
|
|
<p>(19.85 lower to 17.25 higher)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng243er7.tab5_1"><p class="no_margin">Downgraded by 2 increments due to very serious risk of bias: Study authors do not provide necessary details around recruitment and randomisation so outcomes are at risk of selection bias. Study authors also do not provide details around blinding so outcomes are at risk of measurement bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng243er7.tab5_2"><p class="no_margin">Downgraded by 1 increment as population includes males only [Female subjects were excluded because of the potential effect of oestrogen status on corticosteroid-binding globulin (CBG) levels]</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng243er7.tab5_3"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 21.25)</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng243er7.tab5_4"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 18.65)</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng243er7.tab5_5"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 7.8)</p></div></dd></dl><dl class="bkr_refwrap"><dt>f</dt><dd><div id="niceng243er7.tab5_6"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 10.8)</p></div></dd></dl><dl class="bkr_refwrap"><dt>g</dt><dd><div id="niceng243er7.tab5_7"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 7.75)</p></div></dd></dl><dl class="bkr_refwrap"><dt>h</dt><dd><div id="niceng243er7.tab5_8"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 8.55)</p></div></dd></dl><dl class="bkr_refwrap"><dt>i</dt><dd><div id="niceng243er7.tab5_9"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 15.2)</p></div></dd></dl><dl class="bkr_refwrap"><dt>j</dt><dd><div id="niceng243er7.tab5_10"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 8.85)</p></div></dd></dl><dl class="bkr_refwrap"><dt>k</dt><dd><div id="niceng243er7.tab5_11"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed both MIDs (+/− 8.85)</p></div></dd></dl><dl class="bkr_refwrap"><dt>l</dt><dd><div id="niceng243er7.tab5_12"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 6.65)</p></div></dd></dl><dl class="bkr_refwrap"><dt>m</dt><dd><div id="niceng243er7.tab5_13"><p class="no_margin">Downgraded by 2 increments because comparator value was not captured</p></div></dd></dl><dl class="bkr_refwrap"><dt>n</dt><dd><div id="niceng243er7.tab5_14"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 10.9)</p></div></dd></dl><dl class="bkr_refwrap"><dt>o</dt><dd><div id="niceng243er7.tab5_15"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 10.25)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng243er7tab6"><div id="niceng243er7.tab6" class="table"><h3><span class="label">Table 6</span><span class="title">Clinical evidence summary: Dose A (20 mg 0800 h, 10 mg 1600 h) vs Dose B (10 mg 0800 h and 1600 h) vs Dose C (10 mg 0800 h and 5 mg 1600 h) – Blood pressure (BP) outcomes</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng243er7.tab6_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab6_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng243er7.tab6_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab6_1_1_1_2" style="text-align:center;vertical-align:middle;">№ of participants (studies) Follow-up</th><th id="hd_h_niceng243er7.tab6_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab6_1_1_1_3" style="text-align:center;vertical-align:middle;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng243er7.tab6_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab6_1_1_1_4" style="text-align:center;vertical-align:middle;">Relative effect (95% CI)</th><th id="hd_h_niceng243er7.tab6_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng243er7.tab6_1_1_1_5" id="hd_h_niceng243er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with comparator</th><th headers="hd_h_niceng243er7.tab6_1_1_1_5" id="hd_h_niceng243er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with intervention</th></tr></thead><tbody><tr><td headers="hd_h_niceng243er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>24h ambulatory systolic BP - A vs B</b>
|
|
</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean 24h ambulatory systolic BP - A vs B was <b>117</b> mmHg</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2 mmHg lower</b></p>
|
|
<p>(12.52 lower to 8.52 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>24h ambulatory systolic BP - A vs C</b>
|
|
</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean 24h ambulatory systolic BP - A vs C was <b>115</b> mmHg</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0 mmHg</b></p>
|
|
<p>(10.97 lower to 10.97 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>24h ambulatory systolic BP - B vs C</b>
|
|
</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean 24h ambulatory systolic BP - B vs C was <b>115</b> mmHg</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2 mmHg higher</b></p>
|
|
<p>(8.97 lower to 12.97 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>24h ambulatory diastolic BP - A vs B</b>
|
|
</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean 24h ambulatory diastolic BP - A vs B was <b>68</b> mmHg</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2 mmHg higher</b></p>
|
|
<p>(5.01 lower to 9.01 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>24h ambulatory diastolic BP - B vs C</b>
|
|
</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean 24h ambulatory diastolic BP - B vs C was <b>68</b> mmHg</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2 mmHg higher</b></p>
|
|
<p>(4.59 lower to 8.59 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>24h ambulatory diastolic BP - A vs C</b>
|
|
</p>
|
|
<p>follow-up: 6 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean 24h ambulatory diastolic BP - A vs C was <b>68</b> mmHg</td><td headers="hd_h_niceng243er7.tab6_1_1_1_5 hd_h_niceng243er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0 mmHg</b></p>
|
|
<p>(6.59 lower to 6.59 higher)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng243er7.tab6_1"><p class="no_margin">Downgraded by 2 increments due to very serious risk of bias: Study authors do not provide necessary details around recruitment and randomisation so outcomes are at risk of selection bias. Study authors also do not provide details around blinding, so outcomes are at risk of measurement bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng243er7.tab6_2"><p class="no_margin">Downgraded by 1 increment as population includes males only [Female subjects were excluded because of the potential effect of oestrogen status on corticosteroid-binding globulin (CBG) levels]</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng243er7.tab6_3"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 6)</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng243er7.tab6_4"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 6.5)</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng243er7.tab6_5"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 4)</p></div></dd></dl><dl class="bkr_refwrap"><dt>f</dt><dd><div id="niceng243er7.tab6_6"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 3.5)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng243er7tab7"><div id="niceng243er7.tab7" class="table"><h3><span class="label">Table 7</span><span class="title">Clinical evidence summary: Dose A [10mg/5mg HC] vs Dose B [10mg/5mg/5mg HC]</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng243er7.tab7_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab7_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng243er7.tab7_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab7_1_1_1_2" style="text-align:center;vertical-align:middle;">№ of participants (studies) Follow-up</th><th id="hd_h_niceng243er7.tab7_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab7_1_1_1_3" style="text-align:center;vertical-align:middle;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng243er7.tab7_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab7_1_1_1_4" style="text-align:center;vertical-align:middle;">Relative effect (95% CI)</th><th id="hd_h_niceng243er7.tab7_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng243er7.tab7_1_1_1_5" id="hd_h_niceng243er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with Dose B [10mg/5mg/5mg HC]</th><th headers="hd_h_niceng243er7.tab7_1_1_1_5" id="hd_h_niceng243er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with Dose A [10mg/5mg HC]</th></tr></thead><tbody><tr><td headers="hd_h_niceng243er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF-36 - Physical sum scale</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 4 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF-36 - Physical sum scale was <b>40.7</b> points</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>3.2 points higher</b></p>
|
|
<p>(4.66 lower to 11.06 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>SF-36 - Psychological sum scale</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 4 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean SF-36 - Psychological sum scale was <b>46.4</b> points</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.1 points lower</b></p>
|
|
<p>(7 lower to 6.8 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>BSI Global Severity Index</b>
|
|
</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 4 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean BSI Global Severity Index was <b>58.1</b> points</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.2 points lower</b></p>
|
|
<p>(8.15 lower to 7.75 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>Satisfaction with medication</b> assessed with: 100 mm visual analog scale</p>
|
|
<p>Scale from: 0 to 100</p>
|
|
<p>follow-up: 4 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean satisfaction with medication was <b>56.6</b> points</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>5.4 points lower</b></p>
|
|
<p>(25.22 lower to 14.42 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>Sleepiness score 0700</b> assessed with: Stanford Sleepiness Scale</p>
|
|
<p>Scale from: 0 to 7</p>
|
|
<p>follow-up: 4 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean sleepiness score 0700 was <b>2.3</b> points</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.2 points higher</b></p>
|
|
<p>(0.02 lower to 0.42 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>Sleepiness score 1200</b> assessed with: Stanford Sleepiness Scale</p>
|
|
<p>Scale from: 0 to 7</p>
|
|
<p>follow-up: 4 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>g</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean sleepiness score 1200 was <b>1.7</b> points</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0 points</b></p>
|
|
<p>(0.17 lower to 0.17 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>Sleepiness score 1500</b> assessed with: Stanford Sleepiness Scale</p>
|
|
<p>Scale from: 0 to 7</p>
|
|
<p>follow-up: 4 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>h</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean sleepiness score 1500 was <b>1.8</b> points</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0 points</b></p>
|
|
<p>(0.17 lower to 0.17 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>Sleepiness score 1800</b> assessed with: Stanford Sleepiness Scale</p>
|
|
<p>Scale from: 0 to 7</p>
|
|
<p>follow-up: 4 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁⨁◯◯ low<sup>a</sup><sup>,</sup><sup>i</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean sleepiness score 1800 was <b>2.1</b> points</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.4 points lower</b></p>
|
|
<p>(0.57 lower to 0.23 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>Sleepiness score 2200</b> assessed with: Stanford Sleepiness Scale</p>
|
|
<p>Scale from: 0 to 7</p>
|
|
<p>follow-up: 4 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁⨁◯◯ low<sup>a</sup><sup>,</sup><sup>j</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean sleepiness score 2200 was <b>3.4</b> points</td><td headers="hd_h_niceng243er7.tab7_1_1_1_5 hd_h_niceng243er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.7 points lower</b></p>
|
|
<p>(0.99 lower to 0.41 lower)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng243er7.tab7_1"><p class="no_margin">Downgraded by 2 increments for risk of bias (potential for measurement bias in patient-reported outcome, little information provided on deviations from intended interventions).</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng243er7.tab7_2"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 2)</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng243er7.tab7_3"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 3)</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng243er7.tab7_4"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 6.45)</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng243er7.tab7_5"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 13.65)</p></div></dd></dl><dl class="bkr_refwrap"><dt>f</dt><dd><div id="niceng243er7.tab7_6"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 0.16)</p></div></dd></dl><dl class="bkr_refwrap"><dt>g</dt><dd><div id="niceng243er7.tab7_7"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 0.145)</p></div></dd></dl><dl class="bkr_refwrap"><dt>h</dt><dd><div id="niceng243er7.tab7_8"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 0.12)</p></div></dd></dl><dl class="bkr_refwrap"><dt>i</dt><dd><div id="niceng243er7.tab7_9"><p class="no_margin">no imprecision MID (+/− 0.15)</p></div></dd></dl><dl class="bkr_refwrap"><dt>j</dt><dd><div id="niceng243er7.tab7_10"><p class="no_margin">no imprecision MID (+/− 0.25)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng243er7tab8"><div id="niceng243er7.tab8" class="table"><h3><span class="label">Table 8</span><span class="title">Clinical evidence summary: Low dose HC (0.2-0.3 mg/kg) vs High dose HC (0.4-0.6 mg/kg)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab8_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab8_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab8_1_1_1_2" style="text-align:center;vertical-align:middle;">№ of participants (studies) Follow-up</th><th id="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab8_1_1_1_3" style="text-align:center;vertical-align:middle;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab8_1_1_1_4" style="text-align:center;vertical-align:middle;">Relative effect (95% CI)</th><th id="hd_h_niceng243er7.tab8_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng243er7.tab8_1_1_1_5" id="hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with high dose HC (0.4-0.6 mg/kg)</th><th headers="hd_h_niceng243er7.tab8_1_1_1_5" id="hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with low dose HC (0.2-0.3 mg/kg)</th></tr></thead><tbody><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Systolic BP</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean systolic BP was <b>138</b> mmHg</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>5 mmHg lower</b></p>
|
|
<p>(11.08 lower to 1.08 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Diastolic BP</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean diastolic BP was <b>78</b> mmHg</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2 mmHg lower</b></p>
|
|
<p>(5.85 lower to 1.85 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>BMI</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>low<sup>a</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean BMI was <b>27.1</b> kg/m2</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.2 kg/m2 lower</b></p>
|
|
<p>(1.82 lower to 1.42 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired memory: immediate memory</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 0.87</b>
|
|
</p>
|
|
<p>(0.46 to 1.62)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">319 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>41 fewer per 1,000</b>
|
|
</p>
|
|
<p>(172 fewer to 198 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired memory: short-term memory</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 0.75</b>
|
|
</p>
|
|
<p>(0.18 to 3.17)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">85 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>21 fewer per 1,000</b>
|
|
</p>
|
|
<p>(70 fewer to 185 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired memory: delayed memory</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 1.00</b>
|
|
</p>
|
|
<p>(0.41 to 2.44)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">170 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>0 fewer per 1,000</b>
|
|
</p>
|
|
<p>(100 fewer to 245 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired memory: recognition</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 2.00</b>
|
|
</p>
|
|
<p>(0.53 to 7.53)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">64 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>64 more per 1,000</b>
|
|
</p>
|
|
<p>(30 fewer to 417 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired attention: divided attention errors</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 0.86</b>
|
|
</p>
|
|
<p>(0.31 to 2.36)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">149 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>21 fewer per 1,000</b>
|
|
</p>
|
|
<p>(103 fewer to 203 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired attention: visual scanning errors</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 1.00</b>
|
|
</p>
|
|
<p>(0.31 to 3.23)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">106 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>0 fewer per 1,000</b>
|
|
</p>
|
|
<p>(73 fewer to 237 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired executive function: fluency</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 1.00</b>
|
|
</p>
|
|
<p>(0.31 to 3.23)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">106 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>0 fewer per 1,000</b>
|
|
</p>
|
|
<p>(73 fewer to 237 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired executive function: working memory</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 0.75</b>
|
|
</p>
|
|
<p>(0.18 to 3.17)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">85 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>21 fewer per 1,000</b>
|
|
</p>
|
|
<p>(70 fewer to 185 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired executive function: cognitive flexibility</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 1.00</b>
|
|
</p>
|
|
<p>(0.35 to 2.88)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">128 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>0 fewer per 1,000</b>
|
|
</p>
|
|
<p>(83 fewer to 240 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired social cognition</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 1.64</b>
|
|
</p>
|
|
<p>(0.87 to 3.08)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">234 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>150 more per 1,000</b>
|
|
</p>
|
|
<p>(30 fewer to 487 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>Number of patients with impaired psychomotor speed</b>
|
|
</p>
|
|
<p>follow-up: 10 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>47</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 0.71</b>
|
|
</p>
|
|
<p>(0.44 to 1.14)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">511 per 1,000</td><td headers="hd_h_niceng243er7.tab8_1_1_1_5 hd_h_niceng243er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>148 fewer per 1,000</b>
|
|
</p>
|
|
<p>(286 fewer to 71 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng243er7.tab8_1"><p class="no_margin">Downgraded by 2 increments for risk of bias due to missing outcome data.</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng243er7.tab8_2"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 8)</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng243er7.tab8_3"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 4.5)</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng243er7.tab8_4"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed both MIDs (+/− 2)</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng243er7.tab8_5"><p class="no_margin">Downgraded by 2 increments as confidence interval crossed 2 MIDs (0.8, 1.25)</p></div></dd></dl><dl class="bkr_refwrap"><dt>f</dt><dd><div id="niceng243er7.tab8_6"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (0.8, 1.25)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng243er7tab9"><div id="niceng243er7.tab9" class="table"><h3><span class="label">Table 9</span><span class="title">Modified-Release HC tablet vs Standard Glucocorticoid</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng243er7.tab9_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab9_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng243er7.tab9_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab9_1_1_1_2" style="text-align:center;vertical-align:middle;">№ of participants (studies) Follow-up</th><th id="hd_h_niceng243er7.tab9_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab9_1_1_1_3" style="text-align:center;vertical-align:middle;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng243er7.tab9_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng243er7.tab9_1_1_1_4" style="text-align:center;vertical-align:middle;">Relative effect (95% CI)</th><th id="hd_h_niceng243er7.tab9_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng243er7.tab9_1_1_1_5" id="hd_h_niceng243er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with standard glucocorticoid</th><th headers="hd_h_niceng243er7.tab9_1_1_1_5" id="hd_h_niceng243er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with MR-HC</th></tr></thead><tbody><tr><td headers="hd_h_niceng243er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>Change in BMI from baseline</p>
|
|
<p>At 24 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>78</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean change in BMI from baseline was <b>0.7</b> kg/m2</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>1.6 kg/m2 lower</b></p>
|
|
<p>(2.7 lower to 0.5 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>Change in bodyweight from baseline</p>
|
|
<p>At 24 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>78</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean change in bodyweight from baseline was <b>1.9</b> kg</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>4 kg lower</b></p>
|
|
<p>(6.64 lower to 1.36 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>Change in HbA1c from baseline</p>
|
|
<p>At 24 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>78</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean change in HbA1c from baseline was <b>0.1</b> %</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.3 % lower</b></p>
|
|
<p>(0.44 lower to 0.16 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>Change in AddiQoL from baseline</p>
|
|
<p>At 24 weeks (higher is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>78</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>b</sup><sup>,</sup><sup>f</sup><sup>,</sup><sup>g</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean change in AddiQoL from baseline was <b>2</b> out of 10 (AddiQoL score).</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>5 out of 10 (AddiQoL score) higher</b></p>
|
|
<p>(0.89 higher to 9.11 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>Change in infections [flu or flu-like events in 6 mos] from baseline</p>
|
|
<p>At 24 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>78</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>h</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean change in infections [flu or flu-like events in 6 mos] from baseline was <b>− 0.4</b> flu or flu-like events.</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.8 flu or flu-like events. lower</b></p>
|
|
<p>(1.52 lower to 0.08 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>Change in total cholesterol from baseline</p>
|
|
<p>At 24 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>78</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>i</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean change in total cholesterol from baseline was <b>0</b> mg/dL</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>1 mg/dL lower</b></p>
|
|
<p>(14.76 lower to 12.76 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>Serious adverse events</p>
|
|
<p>At 24 weeks (lower is better)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>78</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>j</sup></p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>OR 0.10</b>
|
|
</p>
|
|
<p>(0.01 to 1.73)</p>
|
|
</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">57 per 1,000</td><td headers="hd_h_niceng243er7.tab9_1_1_1_5 hd_h_niceng243er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>51 fewer per 1,000</b>
|
|
</p>
|
|
<p>(57 fewer to 38 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Footnotes</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng243er7.tab9_1"><p class="no_margin">Downgraded by 1 increment as the majority of evidence was of high risk of bias due to bias arising from the randomisation process [single-blind study design, allocation not concealed from patients].</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng243er7.tab9_2"><p class="no_margin">Downgraded by 1 increment because of population indirectness. Population includes people with both primary and secondary AI [50% of population have secondary AI]</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng243er7.tab9_3"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 1.165)</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng243er7.tab9_4"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 2.91)</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng243er7.tab9_5"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 0.145)</p></div></dd></dl><dl class="bkr_refwrap"><dt>f</dt><dd><div id="niceng243er7.tab9_6"><p class="no_margin">Downgraded by 2 increments as the majority of evidence was of high risk of bias due to bias arising from the randomisation process [single-blind study design, allocation not concealed from patients] and measurement of the outcome [risk of measurement bias in patient-reported outcome].</p></div></dd></dl><dl class="bkr_refwrap"><dt>g</dt><dd><div id="niceng243er7.tab9_7"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 4.365)</p></div></dd></dl><dl class="bkr_refwrap"><dt>h</dt><dd><div id="niceng243er7.tab9_8"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 0.8)</p></div></dd></dl><dl class="bkr_refwrap"><dt>i</dt><dd><div id="niceng243er7.tab9_9"><p class="no_margin">Downgraded by 1 increment as confidence interval crossed 1 MID (+/− 13.1)</p></div></dd></dl><dl class="bkr_refwrap"><dt>j</dt><dd><div id="niceng243er7.tab9_10"><p class="no_margin">Downgraded by 2 increments as the confidence interval crossed two MIDS (0.8 to 1.25 default MID)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng243er7tab10"><div id="niceng243er7.tab10" class="table"><h3><span class="label">Table 10</span><span class="title">Unit costs for children for the routine pharmacological management of secondary and tertiary adrenal insufficiency</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab10_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Resource<sup>(a)</sup></th><th id="hd_h_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dose per day</th><th id="hd_h_niceng243er7.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per day</th><th id="hd_h_niceng243er7.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per year</th></tr></thead><tbody><tr><th headers="hd_h_niceng243er7.tab10_1_1_1_1" id="hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Hydrocortisone</i>
|
|
</th><th headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_h_niceng243er7.tab10_1_1_1_3 hd_h_niceng243er7.tab10_1_1_1_4" id="hd_b_niceng243er7.tab10_1_1_1_2" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>8mg/m<sup>2</sup> - 15 mg/m<sup>2</sup></i>
|
|
</th></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Neonate</b>
|
|
</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2mg – 2.5mg</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard release</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2mg – 2.5mg<sup>(b)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.29</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£104.15</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alkindi</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2mg – 2.5mg</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2.70 - £3.38</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£985.50 - £1,231.88</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Combination</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">n/a</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>1 year</b>
|
|
</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.5mg – 4.5mg</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard release</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.5mg – 4.5mg<sup>(b)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.29</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£104.15</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alkindi</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.5mg – 4.5mg</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.73 - £6.08</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,724.63 - £2,217.38</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Combination</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.5mg – 4.5mg<sup>(c)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2.04 - £3.39</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£744.24 - £1,236.99</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>2 years</b>
|
|
</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.5mg – 5.5mg</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard release</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.5mg – 5.5mg<sup>(b)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.29</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£104.15</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alkindi</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">n/a</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Combination</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.5mg – 5.5mg<sup>(d)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£3.39 - £4.74</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,236.99 - £1,729.74</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>5 years</b>
|
|
</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6mg – 7.5mg</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard release</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6mg – 7.5mg<sup>(b)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.21</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£78.11</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alkindi</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">n/a</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Combination</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6mg – 7.5mg<sup>(e)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£5.41 - £4.75</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,976.11 - £1,734.85</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>10 years</b>
|
|
</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9mg – 11mg</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard release</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9mg – 11mg<sup>(f)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.21 - £2.17</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£78.11 - £793.15</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alkindi</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">n/a</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Combination</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9mg – 11mg<sup>(g)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£3.51 - £3.52</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,280.79 - £1,285.90</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>12 years</b>
|
|
</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.5mg – 12mg</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard release</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.5mg – 12mg<sup>(f)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.21 - £2.17</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£78.11 - £793.15</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Combination</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.5mg – 12mg<sup>(h)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.18 - £4.87</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,527.16 - £1,778.65</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>14 years</b>
|
|
</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12mg – 15mg</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard release</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12mg – 15mg<sup>(i)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.21 - £2.97</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£78.11 - £1,083.32</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Combination</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12mg<sup>(j)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.87</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,778.65</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>16 years</b>
|
|
</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13mg – 17mg</td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard release</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13mg – 17mg<sup>(i)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.21 - £2.97</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£78.11 - £1,083.32</td></tr><tr><td headers="hd_h_niceng243er7.tab10_1_1_1_1 hd_b_niceng243er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Combination</td><td headers="hd_h_niceng243er7.tab10_1_1_1_2 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13mg – 17mg<sup>(k)</sup></td><td headers="hd_h_niceng243er7.tab10_1_1_1_3 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£3.54 - £3.57</td><td headers="hd_h_niceng243er7.tab10_1_1_1_4 hd_b_niceng243er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,291.01 - £1,301.78</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng243er7.tab10_1"><p class="no_margin">Source of costs from The British National Formulary (BNF).<a class="bibr" href="#niceng243er7.ref5" rid="niceng243er7.ref5"><sup>5</sup></a> Dosage based committee expert opinion. For children over 1 year assumed the largest dose is given in the morning and the smallest in the evening, mimicking the normal daily rhythm of cortisol secretion.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng243er7.tab10_2"><p class="no_margin">One 10mg tablet used for each dose, assuming four doses daily until age 4 and three doses daily from age 5. Each tablet is crushed and dissolved in water allowing for correct dose to be drawn up and administered. For older children tablets can be split to make up doses. Assumes drug wastage.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng243er7.tab10_3"><p class="no_margin">3.5mg costed as one 2.5mg standard release tablet and 1mg Alkindi granules in capsules; 4.5mg costs as one 2.5mg standard release tablet and 2 mg Alkindi granules in capsules.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="niceng243er7.tab10_4"><p class="no_margin">4.5mg costs as one 2.5mg standard release tablet and 2mg Alkindi granules in capsules;5.5mg costed as one 2.5mg standard release tablet and 3mg Alkindi granules in capsules.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(e)</dt><dd><div id="niceng243er7.tab10_5"><p class="no_margin">6mg costs as one 2.5mg standard release tablet and 3.5mg Alkindi granules in capsules;7.5mg costed as two 2.5mg standard release tablets and 2.5mg Alkindi granules in capsules.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(f)</dt><dd><div id="niceng243er7.tab10_6"><p class="no_margin">Either one 10mg tablet used for each dose, assuming three doses daily, tablets can be split to make up doses or 10mg costed as one 5mg and two 2.5mg standard release tablets.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(g)</dt><dd><div id="niceng243er7.tab10_7"><p class="no_margin">9mg costs as one 2.5mg and one 5mg standard release tablets and 1.5mg Alkindi granules in capsules;11mg costed as one 5mg and two 2.5mg standard release tablets and 1mg Alkindi granules in capsules.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(h)</dt><dd><div id="niceng243er7.tab10_8"><p class="no_margin">9.5mg costs as one 2.5mg and one 5mg standard release tablets and 2mg Alkindi granules in capsules;12mg costed as one 5mg and two 2.5mg standard release tablets and 2mg Alkindi granules in capsules.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(i)</dt><dd><div id="niceng243er7.tab10_9"><p class="no_margin">Either one 10mg tablet used for each dose, assuming three doses daily, tablets can be split to make up doses or 15mg costed as two 5mg and two 2.5mg standard release tablets.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(j)</dt><dd><div id="niceng243er7.tab10_10"><p class="no_margin">Costed as one 5mg and two 2.5mg standard release tablets and 2mg Alkindi granules in capsules.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(k)</dt><dd><div id="niceng243er7.tab10_11"><p class="no_margin">13mg costs as three 2.5mg and one 5mg standard release tablets and 0.5mg Alkindi granules in capsules;17mg costed as one 10mg and one 5mg standard release tablets and 2mg Alkindi granules in capsules.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng243er7tab11"><div id="niceng243er7.tab11" class="table"><h3><span class="label">Table 11</span><span class="title">Unit costs for adults for the routine pharmacological management of secondary and tertiary adrenal insufficiency</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.tab11_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng243er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Resource<sup>(a)</sup></th><th id="hd_h_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dose per day</th><th id="hd_h_niceng243er7.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per day<sup>(b)</sup></th><th id="hd_h_niceng243er7.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per year<sup>(b)</sup></th></tr></thead><tbody><tr><th headers="hd_h_niceng243er7.tab11_1_1_1_1" id="hd_b_niceng243er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Hydrocortisone</i>
|
|
</th><th headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_h_niceng243er7.tab11_1_1_1_3 hd_h_niceng243er7.tab11_1_1_1_4" id="hd_b_niceng243er7.tab11_1_1_1_2" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>15mg – 25mg</i>
|
|
</th></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prescribed as one and a half 10mg tablets a day</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15mg</td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.11</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£39.06</td></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prescribed as two 10mg tablets a day</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15mg – 20mg<sup>(c)</sup></td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.14</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£52.07</td></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prescribed as one 10mg tablet and one 15mg tablet a day</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25mg</td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.19</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£434.72</td></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prescribed as three 10mg tablets a day</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15-mg – 25mg</td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.21</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£78.11</td></tr><tr><th headers="hd_h_niceng243er7.tab11_1_1_1_1" id="hd_b_niceng243er7.tab11_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Modified release hydrocortisone (Plenadren)</i>
|
|
</th><th headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_h_niceng243er7.tab11_1_1_1_3 hd_h_niceng243er7.tab11_1_1_1_4" id="hd_b_niceng243er7.tab11_1_1_6_2" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>15mg – 25mg</i>
|
|
</th></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prescribed as three 5mg tablets a day</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15mg</td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£14.55</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£5,310.75</td></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prescribed as four 5mg tablets a day</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20mg</td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£19.40</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£7,081.00</td></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prescribed as one 20mg tablet a day</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20mg</td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8.00</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,920.00</td></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prescribed as one 5mg tablet and one 20mg tablet a day</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25mg</td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£12.85</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4,690.25</td></tr><tr><th headers="hd_h_niceng243er7.tab11_1_1_1_1" id="hd_b_niceng243er7.tab11_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Prednisolone</i>
|
|
</th><th headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_h_niceng243er7.tab11_1_1_1_3 hd_h_niceng243er7.tab11_1_1_1_4" id="hd_b_niceng243er7.tab11_1_1_11_2" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>3mg – 6mg</i>
|
|
</th></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prescribed as three 1mg capsules a day</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_11_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3mg</td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_11_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.08</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_11_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£30.11</td></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prescribed as one 1mg capsule and one 5mg capsule a day</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_11_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6mg</td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_11_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.06</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_11_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£22.29</td></tr><tr><th headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_h_niceng243er7.tab11_1_1_1_2 hd_h_niceng243er7.tab11_1_1_1_3 hd_h_niceng243er7.tab11_1_1_1_4" id="hd_b_niceng243er7.tab11_1_1_14_1" colspan="4" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Dexamethasone</i>
|
|
</th></tr><tr><td headers="hd_h_niceng243er7.tab11_1_1_1_1 hd_b_niceng243er7.tab11_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dexamethasone</td><td headers="hd_h_niceng243er7.tab11_1_1_1_2 hd_b_niceng243er7.tab11_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.25mg – 0.5mg<sup>(d)</sup></td><td headers="hd_h_niceng243er7.tab11_1_1_1_3 hd_b_niceng243er7.tab11_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.05 - £0.10</td><td headers="hd_h_niceng243er7.tab11_1_1_1_4 hd_b_niceng243er7.tab11_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£19.10 - £39.19</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng243er7.tab11_1"><p class="no_margin">Source of costs from The British National Formulary (BNF).<a class="bibr" href="#niceng243er7.ref5" rid="niceng243er7.ref5"><sup>5</sup></a></p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng243er7.tab11_2"><p class="no_margin">Standard release hydrocortisone is taken either 2 or 3 times daily.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng243er7.tab11_3"><p class="no_margin">For a 15mg dose of hydrocortisone this calculation assumes the additional 5mg is wasted.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="niceng243er7.tab11_4"><p class="no_margin">Cost available in the BNF is for 0.5mg per day. The cost for 0.25mg a day assumes people take half a 0.5mg tablet daily and there is no drug wastage.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng243er7appjtab1"><div id="niceng243er7.appj.tab1" class="table"><h3><span class="label">Table 22</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609085/table/niceng243er7.appj.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng243er7.appj.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reasons for exclusion</th></tr></thead><tbody><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Al Nofal, A., Bancos, I., Benkhadra, K.
|
|
et al. (2017) Glucocorticoid Replacement Regimens in Chronic Adrenal Insufficiency: A Systematic Review and Meta-Analysis. Endocrine Practice
|
|
23(1): 17–31
|
|
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27631672" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27631672</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Alkatib, A. A., Cosma, M., Elamin, M. B.
|
|
et al. (2009) A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. Journal of Clinical Endocrinology & Metabolism
|
|
94(10): 3676–81
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/19773400" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19773400</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Arlt, W. (2004) Dehydroepiandrosterone replacement therapy. Seminars in Reproductive Medicine
|
|
22(4): 379–88
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15635505" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15635505</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Arlt, W. (2006) Dehydroepiandrosterone replacement therapy. Current Opinion in Endocrinology and Diabetes
|
|
13(3): 291–305
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Arlt, W., Callies, F., van Vlijmen, J. C.
|
|
et al. (1999) Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine
|
|
341(14): 1013–20
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/10502590" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10502590</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Arlt, W.; Callies, F.; Allolio, B. (2000) DHEA replacement in women with adrenal insufficiency--pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition. Endocrine Research
|
|
26(4): 505–11
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11196420" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11196420</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bannon, C. A., Gallacher, D., Hanson, P.
|
|
et al. (2020) Systematic review and meta-analysis of the metabolic effects of modified-release hydrocortisone versus standard glucocorticoid replacement therapy in adults with adrenal insufficiency. Clinical Endocrinology
|
|
93(6): 637–651
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32621327" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32621327</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Behan, L. A., Kelleher, G., Hannon, M. J.
|
|
et al. (2014) Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients. European Journal of Endocrinology
|
|
170(1): 141–50
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24123094" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24123094</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Outcomes do not meet review protocol</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bennett, G.; Cussen, L.; O’Reilly, M. W. (2022) The role for long-term use of dehydroepiandrosterone in adrenal insufficiency. Current Opinion in Endocrinology, Diabetes & Obesity
|
|
29(3): 284–293
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/35621180" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35621180</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Review article but not a systematic review</p>
|
|
<p>
|
|
<i>Non-systematic review, NRS included, no MA</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bilger, M., Speraw, S., LaFranchi, S. H.
|
|
et al. (2005) Androgen replacement in adolescents and young women with hypopituitarism. Journal of Pediatric Endocrinology & Metabolism
|
|
18(4): 355–62
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15844469" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15844469</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Binder, G., Weber, S., Ehrismann, M.
|
|
et al. (2009) Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial. Journal of Clinical Endocrinology & Metabolism
|
|
94(4): 1182–90
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/19126625" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19126625</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Boesen, Vb, Borresen, Sw, Christoffersen, T
|
|
et al. (2021) The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments. Endocrine
|
|
71(2): 467–475
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/33063273" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33063273</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Non-randomised - no multivariate analysis</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Brooke, A. M., Kalingag, L. A., Miraki-Moud, F.
|
|
et al. (2006) Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. Journal of Clinical Endocrinology & Metabolism
|
|
91(10): 3773–9
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16849414" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16849414</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Callies, F., Fassnacht, M., van Vlijmen, J. C.
|
|
et al. (2001) Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. Journal of Clinical Endocrinology & Metabolism
|
|
86(5): 1968–72
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11344193" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11344193</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Cameron, D. R. and Braunstein, G. D. (2005) The use of dehydroepiandrosterone therapy in clinical practice. Treatments in Endocrinology
|
|
4(2): 95–114
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15783247" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15783247</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ceccato, F. and Scaroni, C. (2019) Central adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment. Clinical Chemistry & Laboratory Medicine
|
|
57(8): 1125–1135
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30427776" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30427776</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Christiansen, J. J., Andersen, N. H., Sorensen, K. E.
|
|
et al. (2007) Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. Clinical Endocrinology
|
|
66(3): 426–33
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17302879" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17302879</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Christiansen, J. J., Bruun, J. M., Christiansen, J. S.
|
|
et al. (2011) Long-term DHEA substitution in female adrenocortical failure, body composition, muscle function, and bone metabolism: a randomized trial. European Journal of Endocrinology
|
|
165(2): 293–300
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21606192" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21606192</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Christiansen, J. J., Gravholt, C. H., Fisker, S.
|
|
et al. (2005) Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism. European Journal of Endocrinology
|
|
152(1): 77–85
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15762190" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15762190</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Data not reported in an extractable format or a format that can be analysed</p>
|
|
<p>
|
|
<i>Outcomes</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Christiansen, J. J., Gravholt, C. H., Fisker, S.
|
|
et al. (2004) Dehydroepiandrosterone supplementation in women with adrenal failure: impact on twenty-four hour GH secretion and IGF-related parameters. Clinical Endocrinology
|
|
60(4): 461–9
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15049961" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15049961</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Data not reported in an extractable format or a format that can be analysed</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Crowley, R. K., Argese, N., Tomlinson, J. W.
|
|
et al. (2014) Central hypoadrenalism. Journal of Clinical Endocrinology & Metabolism
|
|
99(11): 4027–36
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25140404" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25140404</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Dhatariya, K. K., Greenlund, L. J., Bigelow, M. L.
|
|
et al. (2008) Dehydroepiandrosterone replacement therapy in hypoadrenal women: protein anabolism and skeletal muscle function. Mayo Clinic Proceedings
|
|
83(11): 1218–25
|
|
[<a href="/pmc/articles/PMC2753533/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2753533</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18990320" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18990320</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Dhatariya, K.; Bigelow, M. L.; Nair, K. S. (2005) Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes
|
|
54(3): 765–9
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15734854" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15734854</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Dineen, R., Behan, L. A., Kelleher, G.
|
|
et al. (2020) The contribution of serum cortisone and glucocorticoid metabolites to detrimental bone health in patients receiving hydrocortisone therapy. BMC Endocrine Disorders
|
|
20(1): 154
|
|
[<a href="/pmc/articles/PMC7547490/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7547490</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33036588" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33036588</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Outcomes do not meet review protocol</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Dineen, R., Martin-Grace, J., Ahmed, K. M. S.
|
|
et al. (2021) Cardiometabolic and psychological effects of dual-release hydrocortisone: A cross-over study. European Journal of Endocrinology
|
|
184(2): 253–265
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/33513125" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33513125</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Non-randomised - no multivariate analysis</p>
|
|
<p>
|
|
<i>No control group. Study authors do not make it clear if participants were randomized and if baseline characteristics in treatment groups are comparable</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Gagliardi, L., Nenke, M. A., Thynne, T. R.
|
|
et al. (2014) Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. Journal of Clinical Endocrinology & Metabolism
|
|
99(11): 4149–57
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25127090" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25127090</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Grossman, A. B. (2010) Clinical Review#: The diagnosis and management of central hypoadrenalism. Journal of Clinical Endocrinology & Metabolism
|
|
95(11): 4855–63
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20719838" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20719838</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Review article but not a systematic review</p>
|
|
<p>
|
|
<i>Only 1 database searched</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Groves, R. W., Toms, G. C., Houghton, B. J.
|
|
et al. (1988) Corticosteroid replacement therapy: twice or thrice daily?. Journal of the Royal Society of Medicine
|
|
81(9): 514–6
|
|
[<a href="/pmc/articles/PMC1291759/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1291759</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3184107" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3184107</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Gruber, L. M. and Bancos, I. (2022) Secondary Adrenal Insufficiency: Recent Updates and New Directions for Diagnosis and Management. Endocrine Practice
|
|
28(1): 110–117
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/34610473" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34610473</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hahner, S. and Allolio, B. (2005) Management of adrenal insufficiency in different clinical settings. Expert Opinion on Pharmacotherapy
|
|
6(14): 2407–17
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16259572" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16259572</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hayashi, R., Tamada, D., Murata, M.
|
|
et al. (2019) Glucocorticoid Replacement Affects Serum Adiponectin Levels and HDL-C in Patients With Secondary Adrenal Insufficiency. Journal of Clinical Endocrinology & Metabolism
|
|
104(12): 5814–5822
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31290981" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31290981</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Data not reported in an extractable format or a format that can be analysed</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hayes, A. G.; Rushworth, R. L.; Torpy, D. J. (2022) Risk assessment, diagnosis, and treatment of cancer treatment-related adrenal insufficiency. Expert Review of Endocrinology and Metabolism
|
|
17(1): 21–33
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/34979842" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34979842</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ho, W. and Druce, M. (2018) Quality of life in patients with adrenal disease: A systematic review. Clinical Endocrinology
|
|
89(2): 119–128
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29672878" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29672878</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Libe, R., Barbetta, L., Dall’Asta, C.
|
|
et al. (2004) Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. Journal of Endocrinological Investigation
|
|
27(8): 736–41
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15636426" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15636426</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lovas, K., Gebre-Medhin, G., Trovik, T. S.
|
|
et al. (2003) Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. Journal of Clinical Endocrinology & Metabolism
|
|
88(3): 1112–8
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/12629093" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12629093</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Johannsson, G., Skrtic, S., Lennernas, H.
|
|
et al. (2014) Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments. Current Medical Research & Opinion
|
|
30(9): 1833–47
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24849526" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24849526</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Joseph, R. M., Hunter, A. L., Ray, D. W.
|
|
et al. (2016) Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review. Seminars in Arthritis & Rheumatism
|
|
46(1): 133–41
|
|
[<a href="/pmc/articles/PMC4987145/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4987145</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27105755" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27105755</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study does not contain an intervention relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Joseph, R. M., Hunter, L., Ray, D. W.
|
|
et al. (2015) Shocking? A systematic review of adrenal insufficiency in adults on oral steroids. Arthritis and Rheumatology. Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 67(suppl10)
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study does not contain an intervention relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lee, K. H., Lee, H., Lee, C. H.
|
|
et al. (2019) Adrenal insufficiency in systematic lupus erythematosus (SLE) and antiphospholipid syndrome (APS): A systematic review. Autoimmunity Reviews
|
|
18(1): 1–8
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30408580" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30408580</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Population not relevant to this review protocol</p>
|
|
<p>
|
|
<i>Only included case reviews</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
McHenry, C. M., Bell, P. M., Hunter, S. J.
|
|
et al. (2012) Effects of dehydroepiandrosterone sulphate (DHEAS) replacement on insulin action and quality of life in hypopituitary females: a double-blind, placebo-controlled study. Clinical Endocrinology
|
|
77(3): 423–9
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22420492" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22420492</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Mifsud, S., Gauci, Z., Gruppetta, M.
|
|
et al. (2021) Adrenal insufficiency in HIV/AIDS: a review. Expert Review of Endocrinology & Metabolism
|
|
16(6): 351–362
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/34521306" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34521306</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Mongioi, L. M., Condorelli, R. A., Barbagallo, F.
|
|
et al. (2020) Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review. Endocrine
|
|
67(3): 507–515
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31927751" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31927751</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Panjari, M. and Davis, S. R. (2007) DHEA therapy for women: effect on sexual function and wellbeing. Human Reproduction Update
|
|
13(3): 239–48
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17208951" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17208951</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Peixoto, C., Devicari Cheda, J. N., Nardi, A. E.
|
|
et al. (2014) The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses: a systematic review. Current Drug Targets
|
|
15(9): 901–14
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25039497" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25039497</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Quinkler, M., Beuschlein, F., Hahner, S.
|
|
et al. (2013) Adrenal cortical insufficiency--a life threatening illness with multiple etiologies. Deutsches Arzteblatt International
|
|
110(5152): 882–8
|
|
[<a href="/pmc/articles/PMC3928535/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3928535</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24529304" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24529304</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rice, S. P., Agarwal, N., Bolusani, H.
|
|
et al. (2009) Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. Journal of Clinical Endocrinology & Metabolism
|
|
94(6): 1966–72
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/19318448" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19318448</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sorgdrager, F. J. H., Werumeus Buning, J., Bos, E. H.
|
|
et al. (2018) Hydrocortisone Affects Fatigue and Physical Functioning Through Metabolism of Tryptophan: A Randomized Controlled Trial. Journal of Clinical Endocrinology & Metabolism
|
|
103(9): 3411–3419
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29982583" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29982583</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Secondary publication of an included study that does not provide any additional relevant information</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Srinivasan, M., Irving, B. A., Dhatariya, K.
|
|
et al. (2009) Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women. Journal of Clinical Endocrinology & Metabolism
|
|
94(3): 761–4
|
|
[<a href="/pmc/articles/PMC2681274/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2681274</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19066301" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19066301</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Stacey, M.; Gifford, R. M.; Woods, D. (2021) Safer care for patients with adrenal insufficiency: Weighing the evidence, balancing risks and acknowledging uncertainties. Clinical Medicine, Journal of the Royal College of Physicians of London
|
|
21(5): e541–e542
|
|
[<a href="/pmc/articles/PMC8439507/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8439507</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34507944" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34507944</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
van Thiel, S. W., Romijn, J. A., Pereira, A. M.
|
|
et al. (2005) Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. Journal of Clinical Endocrinology & Metabolism
|
|
90(6): 3295–303
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15797966" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15797966</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Intervention not relevant to this review protocol (DHEAS)</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Vu, T.; Vallabh, M.; Laine, G. (2020) Adrenal Insufficiency and Response to Stress Dose Hydrocortisone in Patients With Cirrhosis and Vasopressor Dependency Using Cirrhosis-Specific Cortisol Thresholds. Annals of Pharmacotherapy
|
|
54(8): 742–749
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31928081" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31928081</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Non-randomised - no multivariate analysis</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Vulto, A., Bergthorsdottir, R., van Faassen, M.
|
|
et al. (2019) Residual endogenous corticosteroid production in patients with adrenal insufficiency. Clinical Endocrinology
|
|
91(3): 383–390
|
|
[<a href="/pmc/articles/PMC6851705/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6851705</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31059146" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31059146</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>comparing case control of primary with an RCT of secondary</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Vulto, A., van Faassen, M., Kerstens, M. N.
|
|
et al. (2022) Susceptibility to Adrenal Crisis Is Associated With Differences in Cortisol Excretion in Patients With Secondary Adrenal Insufficiency. Frontiers in Endocrinology
|
|
13: 849188
|
|
[<a href="/pmc/articles/PMC9065259/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9065259</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35518935" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35518935</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>looking back at people who’ve had an adrenal crisis - not from a perspective of managing the condition</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Werumeus Buning, J., Dimova, L. G., Perton, F. G.
|
|
et al. (2017) Downregulation of cholesteryl ester transfer protein by glucocorticoids: a randomised study on HDL. European Journal of Clinical Investigation
|
|
47(7): 494–503
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28542805" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28542805</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Secondary publication of an included study that does not provide any additional relevant information</p>
|
|
<p>
|
|
<i>genetic/biochem outcomes only</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Werumeus Buning, J., Konopka, K. H., Brummelman, P.
|
|
et al. (2017) Somatosensory function in patients with secondary adrenal insufficiency treated with two different doses of hydrocortisone-Results from a randomized controlled trial. PLoS ONE [Electronic Resource] 12(7): e0180326
|
|
[<a href="/pmc/articles/PMC5501533/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5501533</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28686664" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28686664</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Secondary publication of an included study that does not provide any additional relevant information</p>
|
|
<p>
|
|
<i>Genetic/biochem outcomes only</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Werumeus Buning, J., Kootstra-Ros, J. E., Brummelman, P.
|
|
et al. (2016) Higher hydrocortisone dose increases bilirubin in hypopituitary patients- results from an RCT. European Journal of Clinical Investigation
|
|
46(5): 475–80
|
|
[<a href="/pmc/articles/PMC5111743/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5111743</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26999644" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26999644</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Secondary publication of an included study that does not provide any additional relevant information</p>
|
|
<p>
|
|
<i>genetic/biochem outcomes only</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Werumeus Buning, J., Brummelman, P., Koerts, J.
|
|
et al. (2016) Hydrocortisone Dose Influences Pain, Depressive Symptoms and Perceived Health in Adrenal Insufficiency: A Randomized Controlled Trial. Neuroendocrinology
|
|
103(6): 771–8
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/26646751" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26646751</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Data not reported in an extractable format or a format that can be analysed</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wichers, M., Springer, W., Bidlingmaier, F.
|
|
et al. (1999) The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clinical Endocrinology
|
|
50(6): 759–765
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/10468948" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10468948</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- No useable outcome data</td></tr><tr><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wierman, M. E., Arlt, W., Basson, R.
|
|
et al. (2014) Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism
|
|
99(10): 3489–510
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25279570" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25279570</span></a>]
|
|
</td><td headers="hd_h_niceng243er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|